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ABSTRACT OF DISSERTATION 
 
EVALUATION OF OSTEOGENIC DESIGN FACTORS IN ELECTROSPUN 
POLY(-CAPROLACTONE) NANOFIBER SCAFFOLDS 
 
 Biodegradable bone tissue scaffolds have the potential to impact patients with 
numerous ailments.  Starting with fabrication techniques that produce nano-scale 
features, the ability to manipulate architecture, alter surface chemistry, and 
deliver biological molecules allows for the design of elegant and highly effective 
bone scaffolds.  This work aimed to develop a porous, nanofiber scaffold with 
osteogenic design features the capability to deliver an antibiotic molecule from 
within the nanofibers.  Two osteogenic design factors with unique mechanisms of 
action were selected; hydroxyapatite nanoparticles and oleic acid.  
Hydroxyapatite (HAp) is the primary inorganic phase of natural bone tissue and 
has been used to more closely mimic the extracellular environment of synthetic 
bone tissue scaffolds.  Oleic acid (OLA) is an -9 fatty acid with suspected 
osteogenic effects due to activation of peroxisome proliferator-activator receptors 
(PPARs).  In separate in vitro evaluations, OLA significantly increased osteoblast 
phenotypic behaviors and led to differential expression of the three PPAR 




produced mixed results by inducing a small increase in alkaline phosphatase 
activity, but decreasing expression levels of bone matrix proteins.  An in vivo 
evaluation of biocompatibility revealed that neither design factor increased the 
inflammatory response over control nanofiber scaffolds in paravertebral muscle 
pouches.  However, both factors separately increased new osteoid production.  
Scaffolds with both HAp and OLA elicited the greatest osteogenic response in 
vivo, suggesting positive synergy between the two design factors.  Finally, 
rifampicin (RIF), an antibiotic molecule was loaded into the nanofibers, and its 
release into static bacterial culture was effective in inhibiting bacterial population 
growth for both a Gram-positive and Gram-negative bacterial strain, separately.  
Overall, these nanofiber scaffolds were demonstrated to be effective carriers of 
soluble (OLA, RIF) and insoluble signals (HAp) which can modulate cell 
behaviors.  Future work will aim to incorporate additional osteogenic features into 
the scaffolds and to develop multiple antibiotic release mechanisms from the 
nanofibers.   
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Tissue engineering is a broad field in which the principles of biology and 
engineering are applied in combination to develop a replacement for damaged tissue 
[1].  Bone tissue engineering has drawn a great deal of interest among academic and 
industrial researchers, in part because it represents a puzzling challenge.  Bone itself is 
a prolific tissue and its remodeling is closely associated with a highly prolific cell source 
– bone marrow [2].  Despite this innate regenerative capacity, there remain several 
important shortcomings that clinical treatments for major orthopaedic trauma and 
osteogenesis imperfecta must overcome [3, 4].  Fundamental to solving these problems 
is the recognition that bone tissue functionality is highly dependent on nano-, micro-, 
and macro-structural tissue organization [5].  Thus, a stable fracture site and/or bone-
implant interface is necessary.  Complications associated with a range of diseases and 
injuries continue to impose their financial and lifestyle burdens on patients and health-
care providers. 
Several commercial and pre-clinical products have showed some degree of 
success for enhancing osteogenesis at implantation sites, but none of these have 
displaced the need for bone grafts or metallic implants in large defects [3].  Currently, the 
best clinical treatments for large defects are autografted or allografted bone segments.  
Autografted bone offers a non-immunogenic, biologically-active construct at the expense 
of tissue at a donor site, and thus availability and donor site pain limit this source‘s 
feasibility  [6].  Allografted bone tissue is far more abundant than autografted bone, but 
immunogenicity and sterility are major concerns, and sterilization procedures such as 
irradiation or freeze-drying may alter mechanical and biochemical integrity [7, 8].  
Synthetic tissue scaffolds offer an attractive option for both availability and sterility, but 
these are still considered an inferior clinical choice to both allografts and autografts 




synthetic tissue scaffold design strategies over the last decade and more have aimed at 
making substantial progress in mimicking various features of natural tissue in order to 
enhance osseointegration [10, 11].   
 As synthetic scaffolds have been developed for bone tissue engineering, 
techniques for ex vivo osteoprogenitor cell isolation and manipulation have also been 
developed [4, 9].  It is likely that the clinical implementation of synthetic scaffolds will 
integrate some of these ex vivo cell techniques in conjunction with scaffold design 
features [5].  This project focuses on the latter portion – scaffold design – as a means to 
attain enhanced bone tissue formation and study the efficacy of controlled molecule 
release for a subset of potential scaffold recipients.   
 
1.1.1 Bone Tissue Engineering 
 Progress towards highly-engineered osteogenic scaffolds has been made on 
several tracts including scaffold architecture [12-14], growth factor incorporation [15-17], 
and scaffold chemical composition [18, 19].  In therapeutic applications, such a scaffold 
could grow an osteoprogenitor cell colony and form new bone matrix ex vivo, and then, 
ideally, be delivered as an autograft to the same patient [20].  These osteogenic 
scaffolds would benefit patients undergoing joint replacement [21, 22], tumor resection 
and endoprosthetic implantation [21, 23], maxillofacial repair [24], and skeletal tissue 
healing [25, 26].  An ideal synthetic bone scaffold should support osteoblast phenotypic 
behaviors, in particular, bone matrix deposition [27], while degrading at a rate that allows 
for osseointegration into the native tissue [26]. 
 Any scaffold offered as a potential solution to this design problem requires a 
close examination of many factors regarding the biological response to the scaffold.  




viable, physiologically capable colony of cells on three-dimensional biocompatible 
scaffolds for delivery to patients in need of tissue replacement or regeneration.  It has 
already been established that synthetic extracellular matrices containing a healthy 
population of osteoprogenitor cells will substantially increase osseous tissue formation in 
bone defects [5, 28, 29].  Therefore a great deal of effort has been put forth in the field of 
biomaterials and tissue engineering to develop scaffolds or interfaces that accelerate or 
improve the colonization of marrow stromal cells (MSCs) [30].  
 Once cell colonization is established, the scaffold must support differentiation into 
osteoblasts and neo-mineralization by stem cells within the marrow stromal population 
[31].  In order to accomplish these objectives, many current synthetic bone scaffold 
designs exhibit substantial porosity [27, 32-34], leading to a high surface-area-to-volume 
ratio and enhanced cellular adhesion, and sometimes contain additional osteogenic 
characteristics such as hydroxyapatite or other calcium phosphate [35-38].  Generally, 
investigations into the in vitro behavior of cells on those scaffolds examine alkaline 
phosphatase (ALP) activity, bone nodule formation, and cell morphology [34-36, 38].  
Additional measures of osteoblast activity include the expression of genes for bone 
matrix proteins such as osteocalcin and/or osteopontin genes by polymerase chain 
reaction (PCR), or detection of those proteins by western blotting or enzyme-linked 
immunosorbent assay (ELISA) [32, 39].  These bone matrix proteins add detail to an 
analysis because they are definitive markers of the organic phase of bone matrix 
production rather than mineralization [40-42]. 
 Examining levels of phenotypic expression indicate the capacity for the scaffold 
to support osteoblast behaviors in vitro, but they don‘t necessarily give an indication of 
the specific influences that a scaffold characteristic may be exerting on the cell 




development of a 3-D scaffold so that new tissue develops through the full thickness of a 
scaffold [43].  Thus, scaffold porosity and pore size are two design parameters that 
would likely influence the cellular response.  Furthermore, cellular functions for many cell 
phenotypes within the marrow stromal population, including mesenchymal stem cells, 
osteoblasts, and immune cells [2, 44, 45], are regulated in part by cytoskeletal 
development and organization, which depends on cell-cell and cell-substrate adhesions 
[46, 47].  The degree to which cells are in intimate contact with each other may depend 
on the ability of cells to find each other in a vast 3D scaffold if the cell population can 
easily infiltrate the scaffold.  Thus, examining cellular infiltration, cell adhesion proteins, 
and cytoskeletal arrangement may be important to understanding the biological effects 
of scaffold design parameters. 
 
1.1.2 Bone formation 
A general understanding of the cellular events associated with new bone 
formation is vital to designing osteogenic scaffolds even though the exact mechanism of 
collagen mineralization are still unclear [42].  Within the context of nano-scaled tissue 
scaffolds, it is important to differentiate between the physiologic processes by which 
cells work in concert with each other, and the physico-chemical processes by which cells 
release bone matrix vesicles and these vesicle aggregate into bone nodules.  The 
former results in the designation of whole-bone formation pathways, usually either 
endochondral ossification or intramembranous ossification [40].  Design of nano-scale 
tissue scaffolds allows for the manipulation of nano-scale processes in bone formation 
such as enhancing cellular adhesion [12].  However, given the complexity of both 
heterogeneous and homogeneous bone nucleation, relatively simple alterations to the 




 The key difference between homogeneous and heterogeneous nucleation is 
whether or not there is a supersaturated calcium environments within bone matrix 
vesicles.  Homogeneous bone formation occurs within bone matrix vesicles where the 
fluid within the vesicle is supersaturated with calcium [40].  Some inner leaflet 
phospholipids, most notably phosphatidylserine, contain functional groups, such as 
serine, with very high affinities for calcium [48, 49].  Heterogeneous nucleation occurs at 
sub-saturation concentrations when the surface-ion interaction lowers the interfacial 
surface energy [40].  Heterogeneous nucleation requires surface topography – collagen 
provides this in vivo – as well as non-collagenous proteins (NCPs) such as osteocalcin 
which have affinity for calcium [39, 50, 51].  Although the precise nature of each 
interaction between proteins, lipids, ions, and cells, during bone formation remains 
unclear, the details that are understood should be taken into account when designing an 
osteogenic scaffold. 
 
1.1.3 Cell culture considerations 
With the aim of designing a bone tissue scaffold for therapeutic applications, it is 
important to understand the differences between in vivo and in vitro conditions and how 
those differences might affect the process of evaluating a scaffold.  For example, many 
previous in vitro investigations on nano-structured scaffold materials have used 
genetically engineered cell phenotypes [13, 14, 32, 43, 52].  However the cellular 
response may be a less accurate predictor or the in vivo response because of the 
homogenous experimental population.  A more physiologically accurate approach would 





The benefits of using a heterogeneous cell population center on capturing the 
interaction between cells of different lineages and with different purposes, particularly 
cells of mesenchymal and hematopoietic lineages [44, 45].  Mesenchymal stem cells 
possess the capability to differentiate into multiple cell phenotypes including osteoblasts 
[12, 47].  Hematopoietic stem cells are also able to differentiate into multiple cell 
phenotypes, but many of their phenotypic capabilities are unique to those of 
mesenchymal lineage, particularly immune phenotypes such as monocytes, 
macrophages, and osteoclasts.  By using the whole marrow stromal cell population for in 
vitro studies, several stem cell phenotypes, as well as a vast range of more mature 
phenotypes, are able to interact to produce a more accurate representation of in vivo 
conditions [2].  Still, the best in vitro conditions are unlikely to match in vivo conditions for 
reasons ranging from mechanical stimulation to the ability to recruit cells from the 
general cell population. 
―Living scaffolds‖ or synthetic matrices containing MSC extracts have 
demonstrated accelerated and enhanced bone formation within osseous defects when 
compared with an unpopulated matrix [28, 29].  The marrow stromal population contains 
a heterogeneous, pluripotent population of cells capable of differentiating along multiple 
mesenchymal lineages (e.g., bone [53, 54], ligament [55-57], adipose [57, 58], and 
muscle tissue [59]) and hematopoietic lineages [2].  Tissue culture techniques enable 
the isolation and ex vivo culture of the entire marrow stromal cell population from various 
sources [60], allowing these cells to serve as a model osteogenic cell source for 
evaluating scaffold materials.  Many previous studies that utilized marrow stromal 
extracts cultured and passaged the cell population before seeding them on a scaffold 
material [27, 57, 61, 62].  However, passaging cells may alter the cell response due to 




some phenotypes [57].  Additionally, there is some evidence that chromosomal instability 
associated with extensive passaging may trend a mesenchymal stem cell population 
towards malignancy [64].  For these reasons, a direct culture of bone marrow stromal 
cells provides a better in vitro representation of a synthetic scaffold‘s potential to support 
cellular activity.   
 
1.1.4 Architectural design considerations 
The size scale of synthetic tissue scaffolds is an important scaffold design 
feature, and the existing literature offers a great deal of support for synthetic tissue 
scaffolds with micro- and/or nano-scale features based on greater cellular adhesion and 
phenotypic activity than untextured scaffolds [65-69].  This may be a consequence of 
mimicking highly-featured native tissue architecture exhibited in many natural tissues 
such as bone (Figure 1.1) [70].  In fact, nano-featured scaffolds have been shown to 
influence phenotypic behavior of several cell types, including neural, liver and fibroblastic 
cell types [32, 33, 43, 71].  
While processes such 
as peptide self-assembly can 
produce fibers with diameters 
down to 10 nm, which approach 
that of a collagen fibril [72], 
other processes can produce 
fibers up to several microns in 
diameter [73-75].  Some studies have attempted to optimize fiber diameters for synthetic 
scaffold, but differences in the material chemistry yielded different results.  For example, 
one study with PEOT/PBT found that a fiber diameter of 10 m with nanopores within 







Figure 1.2 - Schematic drawing 
of a basic electrospinning 
apparatus 
the fibers was optimal for MSC adhesion and proliferation [76], while another study 
worked with PLGA and found decreasing cellular responses with fiber diameters below 
800 nm [13], and a third study using carbon nanofibers found that some cell phenotypes 
such as smooth muscle cells were insensitive to fiber diameter while others such as 
chondrocytes have a strong dependence [77].  Perhaps the most important point is that 
architecture is a key design consideration for tissue scaffolds and it should be 
considered in parallel with scaffold chemistry and the phenotype(s) of concern.  
 
1.1.5 Electrospinning 
Electrospinning is a well-established manufacturing technique, first performed in 
the early 1900‘s for use in textiles [78].  It had been largely 
abandoned for years, but has seen a reemergence in 
popularity due, in part, to its simple and inexpensive setup 
[78-80].  Most publications have the same basic 
components to their electrospinning apparatus: a high-
voltage source (up to 50kV), a syringe 
and syringe pump, a fine needle (18-26 
gauge), and a collector (Figure 1.2) [78-
82].  Additional modifications such as 
spinning mandrels [81] or charged 
collectors [83] allow for fiber alignment and patterning.   
 Electrospinning has become very popular within the tissue 
engineering community because it can consistently produce polymeric 
fibers with diameters ranging from less than 100 nanometers up to 
several microns [84].  Under high potential, a Taylor cone of polymer 
Figure 1.3 - 
Illustration of a 
Taylor cone at the 




Figure 1.4 - Fibers spun without 
microspheres (magnification = 190x) 
solution forms at the catheter tip (Figure 1.3).  Once the electrostatic forces overcome 
the viscosity and surface tension, a polymer jet is ejected and it travels from the catheter 
to a grounded collector positioned nearby (4-10 cm) with a trajectory that converges with 
the electric potential field lines.  As the jet travels, the polymer solvent evaporates, 
leading to the deposition of very fine fibers on the grounded collector [75, 80, 84].   
 The fiber properties depend on the processing conditions as well as the nature of 
the polymer(s) and solvent(s).  Ramakrishna et al (2005) describe 13 parameters which 
have influence the morphology of the fibers, although that is not an exhaustive 
description.  An investigation focusing on the electrical input parameters (voltage and 
current) and the charge density of the solution demonstrated nonlinear behavior for each 
of the isolated parameters [75].  Each of these parameters contributes to observable 
properties such as elastic modulus, tensile strength, crystallinity, fiber diameter, fiber 
length, and fiber alignment [78, 81, 83].  With so many variables and interactions 
between variables, and the difficulty of precise control over parameters such as ambient 
temperature and humidity, electrospun fibers are subject to variability in some of the 
aforementioned characteristics.  Fortunately, some parameters (input voltage, needle 
diameter, tip-to-collector distance, and feed rate) are easily and precisely adjustable.  
Adjustments to these parameters facilitate spinning 
for extended periods of time with reasonably 
consistent results for the fiber morphology and 
diameter (Figure 1.4). 
 Since orthopaedic tissues have a micro to 
nano-hierarchical structure that is built up from the 
nanoscale [70], it is desirable to fabricate scaffolds that mimic natural tissue features.  




concentration or adding charged molecules in the spinning solution.  It has been 
demonstrated that adding benzyl trialkylammonium chlorides (BTCs), a class of organo-
soluble salts, to the spinning solutions resulted in more consistent fiber diameters [85].  
However, BTCs are likely to have cytotoxic effects in cell cultures.  These concerns 
could be addressed by adding naturally occurring, charge-carrying molecules such as 
fatty acid salts.  Further, by changing only a few spinning parameters, notably polymer 
concentration, fiber diameter can be predictably increased or decreased [13, 86]. 
 
1.1.6 Synthetic tissue scaffolds in regenerative medicine 
 There exists a large body of support in the literature that tissue scaffolds having 
micro- and/or nano-scale features induce greater cellular adhesion and activity than 
untextured scaffolds [66, 67, 87].  Polymeric nanofibers have already been used as 
scaffolds for in vitro cultures of several distinct cell families such as orthopaedic [52], 
neural [71, 88, 89], and hepatic [90].  Nanofibers are attractive to tissue engineers 
because of the control over such parameters as the porosity of a 3D scaffold, the fiber 
diameter (surface-area-to-volume ratio), the choice of degradation rate, and the 
incorporation of bio-molecules for specific cell phenotype activity or 
antibiotic/antimicrobial characteristics.   
 Controlled release or triggered delivery of therapeutic compounds is currently a 
highly-active research area.  There are too many approaches to summarize completely, 
but some of the more common strategies include encapsulation in liposomes and lipid 
micelles [91, 92], polymer micro- and nano-spheres or fibers [93-95], and conjugated 
molecules [96-98].  Drug-loaded polymers have the attractive feature of being applicable 
in processes, such as electrospinning, that are relatively robust, scalable, and 




when encapsulated in liposomes and micelles, which can be avoided by encapsulating 
such a drug in polymers [94].  Designing electrospun nanofibers for drug delivery is very 
similar to designing nanofibers for tissue engineering.  The key difference is that the 
polymer solution properties will change due to the added molecule.  This is logical since 
fiber diameter and scaffold morphology are influenced by charge-carrying additives that 
may increase or decrease the stability of the electrospinning process [93].   This is 
important to keep in mind for the aforementioned cellular response as well as the 
changes to the release rate and duration [99, 100].   
The dual-importance of fiber diameter to both the release profile and cell 
proliferation illustrates a technological intersection often referred to as regenerative 
medicine.  Regenerative medicine has been described as the result of combined efforts 
to restore, maintain, and enhance normal cell or tissue function through combined 
technologies from material science, biology, and engineering [68, 101-103].  The specific 
mechanisms of action would strongly depend on the application for which a device is 
designed.  For example, a ―smart biomaterial‖ for cancer treatment might release one or 
more anti-cancer drugs conjugated with targeting molecules that is designed to maintain 
a biologically relevant time and concentration level.  After the drug(s) have been 
completely released, the remaining biomaterial contains architecture and chemistry that 
promotes tissue regeneration and a return to normal cell and tissue function.  Such a 
material does not yet exist, but a search through the current literature yields thousands 
of publications on developing the constitutive technologies [33, 48, 94, 104-107]. 
  
1.1.7 Poly(-caprolactone) as a tissue scaffold 
 Electrospinning can produce micro- and nano-scale fibers for any polymer that 




for an electrospun tissue scaffold is fairly vast.  Among the most common synthetic 
polymers used as nanofibrous tissue scaffolds are poly(lactic acid) (PLA), poly(glycolic 
acid) (PGA), poly(caprolactone) (PCL), and poly(ethylene glycol) (PEG) [74].  PCL is a 
semi-crystalline, biocompatible, aliphatic polyester [108] that has attracted increasing 
interest in the tissue engineering community over the past 10-15 years.  It is 
biodegradable, with a relatively slow degradation rate [93], and readily-metabolized 
degradation products add to its appeal in biological applications [9, 109].  As a result, it 
is generally regarded as a good scaffold material for both hard and soft tissues [32, 88]. 
 PCL degrades by hydrolysis of its ester bond.  The degradation rate of a thick 
(>several cm) piece of PCL is on the order of years in the absence of enzymes [110].  
Erosion resulting from bulk PCL hydrolysis degradation is generally regarded as surface 
erosion [111].  However, when the size of architectural features is decreased down to 
the nanoscale, degradation times for PCL in vitro is on the order of months rather than 
years, even when enzymes are excluded from the local environment.   Part of the 
increased degradation rate may be taken as dependence on surface-area-to-volume 
ratio [86].  In this case of nano-featured scaffolds, erosion changes from surface to bulk 
erosion because water is able to move through the polymer faster than hydrolysis takes 
place [111].   
 For design cases when drug release is of concern, which is one of the appealing 
aspects of nano-structured degradable scaffolds [108, 112], controlled release can be 
predicted based on the degradation mechanisms [113, 114].  Several models have been 
developed that can predict the degradation behavior of a scaffold based on the polymer 
characteristics (molecular weight, hydrophobicity/hydrophilicity, degradation 
mechanisms) and scaffold morphology (fiber/sphere diameter, porosity) [100, 115, 116].  




PCL, provide a means for accurately interpreting results from experimental degradation 
studies.  PCL degradation can be divided into two stages; first a reduction in molecular 
weight down to ~5000 g/mol due to chain scission, followed by measurable weight loss 
in the second stage [108].  During the first stage, the amorphous regions preferentially 
undergo cleavage of the ester bond by hydrolysis, primarily because water can 
penetrate these regions with much greater ease than the crystalline regions [117].  Any 
loss of mass during this stage is unlikely to be within the limits of detection for 
gravimetric methods.  However, as the average molecular weight of the polymer chains 
decreases, the shortened chains become increasingly mobile, which leads to the second 
stage with measurable weight loss [108].  Measured weight loss corresponds to the 
release of PCL chains, which are metabolized through the tricarboxylic acid cycle in vivo 
[9].  The presence of enzymes and lipases will increases the degradation rate in a 
concentration-dependent manner [109].   
 This measured weight loss, referred to as erosion, contributes to drug release by 
directly releasing the drug as the polymer carrier erodes as well as increasing the 
surface area in contact with the liquid medium into which the drug is diffusing.  Thus, 
these release models are often referred to as diffusion-degradation-erosion [114].  
Depending on the several factors including polymer crystallinity and fiber/particle size 
[118], the release profile may be manipulated to be linear/quasi-linear, ―S‖ shaped, or 
hyperbolic [114].  In all three cases, information regarding the degradation behavior, 
crystallinity, and drug concentration within the polymer and liquid medium should be 
taken into account. 
 




One of the complications associated with orthopaedic surgery operations is 
sepsis, also referred to as osteomyelitis when the infection is in bone tissue [119, 120].  
Post-operative antibiotic regimens are appealing as prophylactic measures despite high 
sterility standards in operating rooms.  This preventative measure is vital for patients 
undergoing surgery for highly infection-prone cases such as open fractures [121].  
Antibiotic-resistant bacterial strains have reduced the numbers of effective antibiotics 
[120], and this has been highlighted by the much-publicized bacterial strains referred to 
as methacillin-resistant staphylococcus aureus (MRSA) [122].  The consequences of 
surgery-related sepsis include revision surgery, tissue debridement, and the long-term 
side effects of aggressive systemic antibiotic doses [123]. 
  Some antibiotics are effective, but not effective when administered orally, such 
as gentamicin.  Gentamicin is an aminoglycoside, a class of antibiotic drugs that do not 
absorb through the gut.  Aminoglycosides are sometimes administered orally in order to 
clean out the gut from microbes, but otherwise it is administered directly to the area of 
interest (i.e a topical cream for skin infections) or intramuscularly/intravenously [124].  
Aminoglycosides work through several mechanisms, most notably by irreversibly binding 
the 30s (or in a few cases the 50s) ribosomal subunit, thus arresting protein synthesis.  
Additionally, they also sequester ions from a biofilm, opening up cell membrane pores, 
which is an effective bactericidal action [125].  Other antibiotics such as rifampicin (RIF) 
are equally appealing for localized delivery simply to avoid systemic toxicity [126].  As an 
added benefit of localized delivery, multiple antibiotic release would be an effective 
strategy to address heterogeneous infection populations with differing resistances.  For 
example, RIF inhibits prokaryotic RNA polymerases but has no effect on ribosomal 
protein translation [127-129].  By combining RIF with gentamicin, which blocks ribosomal 




several  substrates for localized antibiotic delivery have been developed, although only a 
few, such as antibiotic-loaded bone cements [130], have progressed to clinical use [131].   
 
1.1.9 Aims of this study 
 This study aims to design a multifunctional bone tissue engineering scaffold that 
can be used to locally deliver an antibiotic agent while promoting new bone formation.  
The analysis will be divided into three stages: 
1. Develop consistent nanofiber scaffold architecture using electrospinning and 
evaluate the osteogenic influence of the nanofibrous architecture 
2. Incorporate and evaluate the efficacy of two osteogenic design factors – oleic 
acid and hydroxyapatite nanoparticles 
3. Deliver a model antibiotic from the nanofibrous matrix and evaluate its 
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2.1 Chapter summary 
This research section provided the basis for the research contained in chapters three 
and four.  Previous investigations had examined in vitro and in vivo cytocompatibility for 
nanofiber scaffolds fabricated from a wide range of polymers, but none had performed a 
direct comparison of nanofiber scaffolds against smooth surfaces in osteogenic 
conditions.  In order to demonstrate that nanofiber scaffolds would increase cell 
responses in maintenance and osteogenic conditions, nanofiber poly(-caprolactone) 
(PCL) scaffolds were fabricated by electrospinning along with smooth PCL discs.  
Marrow stromal cells (MSCs) were isolated from rats and cultured in vitro on either 
material to assess short-term cytocompatibility and long-term osteoblast phenotypic 
behaviors.  The short-term cytocompatibility results indicated that nanofiber scaffolds 
supported greater cell adhesion and viability compared with smooth surfaces.  In 
osteogenic conditions, MSCs cultured on nanofiber scaffolds also displayed increased 
levels of alkaline phosphatase activity for 3 weeks of culture. Calcium phosphate 
mineralization was substantially accelerated on nanofiber scaffolds compared to control 
surfaces as indicated through von Kossa and calcium staining, scanning electron 
microscopy and energy-dispersive X-ray spectroscopy.  Increased levels of intra- and 
extracellular levels of osteocalcin and osteopontin were observed on nanofiber scaffolds 
using immunofluorescence techniques after 3 weeks of culture. This section 
demonstrated the enhanced tissue regeneration property of nanofiber scaffolds over 
smooth surfaces.  Furthermore, research into chemical and biological design factors on 
nanofiber scaffolds should control or account for the effects of nanofibrous architecture. 
 
2.2 Motivations and aims 
Progress towards highly engineered osteogenic scaffolds was described in the 




and maintaining a viable, physiologically capable colony of cells on three-dimensional 
biocompatible scaffolds for delivery to patients in need of tissue replacement or 
regeneration. It has already been established that the use of synthetic extracellular 
matrices containing a healthy population of osteoprogenitor cells will substantially 
increase osseous tissue formation in bone defects [5, 28, 29]. Therefore a great deal of 
effort has been made in the field of biomaterials and tissue engineering to develop 
scaffolds or interfaces that accelerate or improve the colonization of marrow stromal 
cells (MSCs) [30]. Existing literature offers a great deal of support for tissue scaffolds 
with micro- and/or nanoscale features because of greater cellular adhesion and 
phenotypic activity than non-textured scaffolds [65-69]. These improvements may a 
result of mimicking the highly featured native tissue architecture exhibited in many 
natural tissues. 
 ‗‗Living scaffolds‖ or synthetic matrices containing bone MSC extracts have 
demonstrated accelerated and enhanced bone formation within osseous defects when 
compared with an unpopulated matrix [28, 29].  The marrow stromal population contains 
a heterogeneous, pluripotent population of cells capable of differentiating along multiple 
mesenchymal lineages (e.g. bone [53, 132], ligament [55, 57, 133], adipose [57, 58] and 
muscle tissue [59]) as well as along immune and hematopoietic cell lineages [2]. Tissue 
culture techniques enable the isolation and ex vivo culture of the entire marrow stromal 
cell population from various sources [134], allowing these cells to serve as a model 
osteogenic cell source for evaluating scaffold properties.   
Previous studies that utilized MSCs, cultured and passaged these cells before 
seeding them on a scaffold material [57, 61, 62, 135]. However, passaging cells may 




cell‘s ability to differentiate into some phenotypes [57]. Furthermore, passaged cell 
populations do not represent the cellular diversity 
of the bone marrow stromal population because of the elimination of non-adherent cells. 
Osteo-immuno cross-talk may play an important role in how osteoprogenitor cells and 
immature osteoblasts behave on the scaffold [2, 44, 45, 136]. For these reasons, a direct 
culture of bone MSCs would provide a better in vitro representation of a synthetic 
scaffold‘s potential to support cellular activity. 
In this chapter, poly(-caprolactone) (PCL) nanofiber scaffolds were evaluated 
against control surfaces for their support of osteogenic differentiation of MSCs.  PCL 
scaffolds were fabricated by electrospinning to produce nanofiber architecture, and 
these scaffolds were characterized in terms of their architectural feature size.  Then cell 
responses to the scaffolds and control surfaces were measured in maintenance and 
osteogenic conditions separately.  
 
2.3. Materials and methods 
 This section provides the details for experimental methods used in each section.  It 
includes the conditions and procedures for manufacturing nanofiber scaffolds, harvesting 
bone marrow stromal cells from rats, sterilizing scaffolds and seeding cells onto the 
scaffolds, and analyzing the cell responses to the scaffolds.   
 
2.3.1. PCL nanofiber scaffold fabrication 
PCL nanofiber scaffolds were fabricated using an electrospinning technique. The 
electrospinning apparatus consisted of a syringe pump (Harvard Apparatus), a glass 
syringe (Hamilton, model 1010), Teflon fluidic tubing (Hamilton, model 86510), a 20-




(Hamilton, model 86511). A high-voltage power source (Gamma High Voltage Research, 
model ES30P-10W/DAM) was 
connected to the catheter tip with a standard alligator clamp.  The collector consisted of 
an aluminum foil fastened onto a 0.5 in. thick copper plate (McMaster Carr, Robbinsville, 
NJ) with electrical tape and positioned horizontally below the catheter.   
Polymer solution was prepared by dissolving oleic acid sodium salt (OLA) (Sigma) in 
methanol. PCL pellets (Mw = 80,000, Sigma) were dissolved in chloroform and the 
polymer solution was mixed with OLA in methanol on a magnetic stir plate to produce a 
homogeneous mixture with a 4:1 chloroform:methanol volume ratio. The final solution 
was 12% solid w/w and the PCL:OLA ratio of the solid weight was 97:3. The volumetric 
flow rate was 2.8 ml/h, applied voltage 21 kV and tip-to-collector distance 10 cm. 
Scaffolds were sputter-coated with 10 nm of gold and imaged under a scanning electron 
microscope to evaluate the nanofiber architecture. Fiber diameters were computed using 
the image analysis system built into the scanning electron microscope. Smooth PCL 
(control) surfaces were fabricated by sintering PCL pellets (Mw = 80,000, Sigma) on a 
glass plate in a 10 mm Teflon washer. The resulting discs were then allowed to air-cool 
before being removed from the glass surface. 
 
2.3.2. Isolation of bone marrow stromal cells 
MSCs were isolated from male Wistar rats (Rattus norvegicus) supplied by Harlan 
Sprague Dawley, Inc. (separate time points, unmixed cell populations). The animal 
protocol was approved by the Colorado State University Animal Care and Use 
Committee. This Committee is in compliance with the NIH Guide for Care and Use of 
Laboratory Animals. Limbs were aseptically removed from recently killed animals, and 




to expose the bone marrow cavity. In a 50 ml conical tube, marrow was repeatedly 
flushed with culture medium (-Minimum Essential Medium (-MEM) with 10% fetal 
bovine serum (FBS, Sigma) and 1% penicillin/streptomycin (pen/strep, Sigma)) using 10 
ml syringes with 18 and 25 gauge needles. Media containing cells and debris was 
filtered with a 70 m nylon filter into a clean tube, and the cells were counted using a 
hemocytometer before seeding. Control (smooth PCL) and nanofiber scaffold (both discs 
with area 0.7 cm2) were sterilized by exposing them to UV light for 60 min followed by 
soaking in 70% ethanol for 60 min. The substrates were then washed twice with warm 
PBS followed by warm culture media prior to MSC seeding. Cells were seeded on 
scaffolds in a 24-well plate at a density of 1 million cells per well. Cultures were 
incubated at 37 oC under 5% CO2 for the duration of the study. Half of the media was 
changed at day 4. On day seven, the media was replaced with osteogenic differentiation 
media (-MEM with 10% FBS, 1% pen/strep, 10-8 M dexamethasone, 50 g/ml ascorbic 
acid, 8 mM -glycerolphosphate).  All test and control surfaces were cultured and 
assayed in triplicate at each time point specified (i.e. one, two or three weeks post-
differentiation).  Media was changed every two days for up to three weeks.  MSC 
response was investigated in two phases: 
 
(a) Cell adhesion, proliferation and viability up to seven days of initial culture (short-
term). This time point is in conjunction with the time required for adherent progenitor 
cells in the bone marrow to adhere and proliferate on the scaffold surface. 
 
(b) Cell osteogenic differentiation and matrix production for up to three weeks after 




differentiation phase to see significant changes in the expression of bone marker 
proteins as well as mineralization on the scaffold surfaces. 
 
2.3.3. Short-term MSC response on nanofiber scaffolds 
After one, four, and seven days of culture, cell responses to the scaffolds were 
investigated through cell adhesion, viability (metabolic activity) and morphology. Live cell 
adhesion was investigated using calcein AM (Invitrogen) (excitation 485 nm, emission 
530 nm).  Calcein AM can penetrate live cell membranes, where the AM is cleaved and 
the resulting calcein molecule fluoresces green. The cells were incubated in 2 M of 
calcein AM in PBS for 45 min and then imaged with a fluorescence microscope (Zeiss) 
with appropriate filters. Images were analyzed (ImageJ, NIH) to compute the per cent 
area covered by live cells for comparison with the cell viability assay.   
Cell viability was measured after 1 and 4 days of culture (log-phase growth) using a  
commercially available MTT assay kit (Sigma).  Adhered cells were incubated at 37 oC 
for 3 h in a 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) solution.  
Mitochondrial dehydrogenases of viable cells cleave the tetrazolium ring, yielding purple 
formazan crystals. Formazan crystals were then dissolved in the MTT solvent with 10 
vol.% Triton-X. The optical density (OD) of the solvent is proportional to the 
mitochondrial activity of the cells on the surface. OD was measured at 570 nm using a 
spectrophotometer (FLUOstar Omega, BMGLabtech, Durham, NC). Background 
absorbance at 690 nm was subtracted from the measured absorbance.  
Cell morphology on control surfaces and nanofiber scaffolds was evaluated after 1, 2 
and 7 days of culture using field emission scanning electron microscopy (SEM, JEOL 
JSM-6500F). The scaffolds were gently removed from the culture media and immersed 




fixing solution (3% glutaraldehyde with 0.1 M sucrose and 0.1 M sodium cacodylate in 
deionized water) for 45 min, rinsed in a buffer solution (fixing solution without 
glutaraldehyde) and then dehydrated in increasing concentrations of ethanol (30%, 50%, 
70%, 90% and 100%) for 10 min each. After dehydration, the scaffolds were immersed 
in hexamethyldisilazane for 10 min and were air-dried. The scaffolds were stored in a 
desiccator until further characterization. They were then sputter-coated with 10 nm of 
gold and imaged by SEM. Particular attention was paid to the shape of adhered cells, 
the location of cells on the scaffold and any characteristics of filopodia adhesions to 
scaffold features. 
 
2.3.4. Long-term MSC response on nanofiber scaffolds 
MSC responses to the nanofiber scaffolds were investigated 1, 2 and 3 weeks after 
providing the cells with osteogenic differentiation media. Alkaline phosphatase (ALP) 
activity, calcium and phosphate deposition, and extracellular matrix (ECM) protein 
production were used to assess the osteoconductivity of the nanofiber scaffolds. 
Nanofiber and control scaffolds were removed from the culture media and rinsed twice in 
PBS prior to analysis. 
To determine the ALP activity, the adhered cells were lysed with Cell Lytic™ solution 
(Sigma) for 1 h. A commercially available ALP colorimetric assay kit (Quantichrome™, 
BioAssay Systems) was used to quantify ALP concentration in the lysate. Briefly, ALP 
catalyzes the reaction of p-nitrophenolphosphate to p-nitrophenol and phosphate.  p-
Nitrophenol was measured using a plate reader (yellow, 405 nm) at 1 and 4 min in order 
to determine the concentration of ALP in the lysate. ALP was calculated using the 
guidelines provided by the manufacturer. Further, the total protein content of the lysate 




solution was measured using a plate reader at a wavelength of 570 nm. The absorbance 
was then converted to protein content using an albumin standard curve to determine the 
amount of intracellular protein. All the ALP data was normalized with total protein content 
to account for changes in number of cells present on each surface.   
In order to stain the scaffolds for phosphate, they were rinsed twice with cacodylate 
buffer and then immersed in 4% paraformaldehyde (w/v) in cacodylate buffer for 10 min. 
They were then rinsed with deionized water and a solution of silver nitrate in deionized 
water was then added for 20 min, allowing the phosphate and silver nitrate to react to 
form a brown precipitate. The reaction was spontaneously stopped by rinsing three times 
with deionized water. Scaffolds were dried in a desiccator and digital images of stained 
surfaces were captured using a Canon PowerShot SD1000.  
In order to stain the scaffolds for calcium, they were rinsed twice in cold (4 oC) 
Ringer‘s solution. They were then immersed in cold 4% paraformaldehyde (w/v) in PBS 
solution for 10 min, rinsed in cold deionized water, and submerged in cold Alizarin red 
solution (2 wt%) in sodium hydroxide for 10 min. The scaffolds were rinsed three times 
with cold deionized water and allowed to dry in a desiccator. Calcium forms a complex 
with Alizarin red S via a chelation process and the end-product is birefringent. Digital 
images of stained surfaces were captured using a Canon PowerShot SD1000. 
Cell morphology was investigated using SEM as described earlier. Samples 
prepared for SEM were also examined for surface elemental composition using an 
energy-dispersive X-ray spectroscopy (EDS) probe (Thermo Electron, Noran System) 
attached to the JEOL JSM-6500F electron microscope. EDS was used to detect 
mineralization (calcium and phosphorus) on the samples. Instrument aperture and probe 
current were adjusted to give a dead time of 15–20%. Surfaces were analyzed for 5 min 




different elements present. Spatial element mapping was performed by grouping pixels 
with similar atomic spectra.  
After 3 weeks in osteogenic media, scaffolds were removed and immunolabeled for 
osteopontin (OC) and osteocalcin (OP). Cells were fixed by immersing in 3.7% 
paraformaldehyde (w/v) in PBS for 10 min followed by permeabilization in a 1% Triton-X 
in PBS solution for 10 min. A blocking serum with 40 g/mL trypan blue (Sigma) and 100 
g/mL bovine serum albumin in PBS was used to prevent non-specific antibody binding. 
After rinsing the scaffolds with PBS, they were incubated in either osteopontin primary 
antibody (1:100 in PBS, V-19 purified goat polyclonal antibody of human origin, Santa 
Cruz Biotechnology) or osteocalcin primary antibody (1:100 in PBS, P-18 purified goat 
polyclonal antibody of mouse origin, Santa Cruz Biotechnology) for 1 h. After an 
additional blocking step and PBS wash, samples were then incubated in FITC-
conjugated secondary antibodies for osteocalcin and osteopontin (1:200 donkey antigoat 
IgG, Santa Cruz Biotechnology) for 45 min. Samples were rinsed once more before 
imaging with 470 nm excitation wavelength using a fluorescence microscope (Zeiss).  
 
2.3.5. Statistical analysis 
All scaffolds were cultured and assayed in triplicate at each time point specified. All 
the studies were conducted in triplicate using different animals as the MSC source for 
each study. The data was pooled from the studies using different cell sources (n = 6). All 
the statistics presented here as a mean ± standard deviation. A two-tailed, unpaired t-








Figure 2.1 – SEM images of nanofiber scaffolds at 150x (A) and 
13,000x (B) magnification.  Fiber diameter histogram with mean and 
standard deviation are also presented 
C 
2.4.1. Fabrication of nanofiber scaffolds 
In this study, nanofiber scaffolds were fabricated using electrospinning to be bead-
free, and characterized using SEM in terms of their mean fiber diameters (Figure 2.1(a–
c)). Fiber diameters for the scaffolds used in this study were consistent, with a mean 
fiber diameter of 372 nm and standard deviation of 179 nm (Figure 2.1(c)). 
Approximately 90% of fiber diameters were between 200 and 500 nm, although 
occasional extreme outliers were observed up to nearly 2 m and were included in the 
statistical analysis (nmin = 12).  
 
2.4.2. Short-term MSC response on nanofiber scaffolds 
The ability of 
nanofiber scaffolds 
to support MSC 
adhesion and 
proliferation was 
evaluated using live 
cell fluorescence 
staining and MTT 
assay. Cells were 
stained with the live 
cell stain calcein 
AM. Figure 2.2 
shows fluorescence 




ImageJ software was used to calculate the cell coverage on control and nanofiber 
scaffolds (Figure 2.3(a)).   
 
Cell viability was investigated using a commercially available MTT assay. The 
measurements were taken after 1 and 4 days of culture since this time period is 
associated with the log-phase growth of the cell population. Our results suggested that 
MSCs are viable on both nanofiber scaffolds and control surfaces for up to 4 days in 
culture (Figure 2.3(b)). Further, the cell viability on nanofiber scaffolds was significantly 
 
Figure 2.3 – Quantitative measurements for cell coverage (A) from calcein AM stains and 
metabolic activity (B) measured by MTT assay 
 
 





Figure 2.5 – Intracellular ALP measured 
by colorimetric assay. Star denotes 
statistically significant (p<0.05) difference 
within a time point 
greater than control surfaces at both time points. To visualize morphological changes in 
MSCs, SEM images were taken after 1, 4 and 7 days of culture (Figure 2.4). SEM 
analysis supported the fluorescence microscopy results that the MSCs preferentially 
adhere, spread and colonize on nanofiber scaffold as compared to control surfaces. 
 
2.4.3. Long-term MSC response on nanofiber scaffolds 
The ability of nanofiber scaffolds to support osteogenic differentiation was evaluated 
using biochemical assays and 
immunofluorescence imaging for bone 
matrix proteins. ALP cleaves organic 
phosphate esters and is a key component 
of bone matrix vesicles. The ALP patterns 
observed over the 3 week experimental 
period (4 week total culture time) for 
nanofiber scaffolds demonstrated 
elevated ALP levels after 3 weeks of 
 
Figure 2.4 – SEM images of cells on NF scaffolds or smooth control surfaces at 1, 4, 





Figure 2.6 – SEM images of smooth control surfaces (a, c, e) and nanofiber scaffolds 
(b, d, f) after 1, 2, and 3 weeks in osteogenic media.  Alizarin calcium staining (red) and 
von Kossa phosphate staining (brown) digital images also pictured 
culture compared to the control surfaces (Figure 2.5) [87, 137, 138].  Mineralization 
patterns were examined qualitatively by SEM/EDS, Alizarin calcium staining and von 
Kossa staining. Figure 1.6 shows digital images of the stained surfaces (calcium (red) on 
top; phosphate (brown) stain on bottom) along with SEM images after 3 weeks of culture 
on both nanofiber scaffolds and control surfaces. SEM images and staining results 
indicated that cells seeded on nanofiber scaffolds display accelerated mineralization 
compared to control (smooth) surfaces.  EDS scans (Figure 2.7) also showed greater 
calcium and phosphorous peaks for mineral deposits on nanofiber scaffolds than on 
control surfaces, indicative of greater amounts of both elements. An EDS mapping tool 




deposits were Ca–P. OP and OC 
were imaged using 
immunofluorescent staining after 3 
weeks in osteogenic medium. 
Immunofluorescent staining for OP 
and OC revealed different deposition 
patterns between the nanofiber 
scaffolds and control surfaces. 
Greater amounts of both bone matrix proteins were evident on the nanofiber scaffolds, 
with many rough-shaped (mineral deposits) and cell-shaped objects visible (Figure 2.8 
(c and d)) compared to that on control surfaces (Figure 2.8 (a and b)). One particularly 
interesting finding from the nanofiber scaffolds was that both stains were observed within 
the scaffold because of strong backlighting of nanofiber features, strongly suggesting 
that osteoblasts had migrated to the scaffold interior and were actively producing organic 
bone matrix components (Figure 2.8 (e and f)).  
 
2.5. Discussion 
Nanofiber scaffolds fabricated by electrospinning have been shown to be excellent 
tissue scaffolds for several unique cell phenotypes [32, 71, 88, 139]. In this study, 
nanofiber scaffolds were fabricated to be bead-free and were characterized using SEM 
in terms of their mean fiber diameters (Figure 2.1 (a–c)). Fiber diameter has been 
shown to influence the cellular response to multiple nanofiber materials in a manner that 
is co-dependent on the fiber material [76, 139-141].  
Fiber diameters for the scaffolds used in this study were consistent, with a mean 
fiber diameter of 372 nm and standard deviation of 179 nm (Figure 2.1(c)). 
 
Figure 2.7 – Combined SEM (a) and EDX 






Figure 2.8 – Immunofluorescent images (a-d, f) and SEM 
image (e) after 3 weeks in osteogenic media.  
Magnification for a-d is 10x, scale bar is 50 m.  
Magnification for f is 40x, scale bar is 100 m.  
Magnification for e is 1000x, scale bar is 10 m 
Approximately 90% of fiber 
diameters were between 
200 and 500 nm, although 
occasional extreme 
outliers were observed up 
to nearly 2 m and were 
included in the statistical 
analysis. In order to 
increase the fiber diameter 
consistency, OLA was 
included at 3% of the total 
solid weight, which 
stabilized the process by 
adding charge to the 
solution [85]. The result 
was fibers with an estimated standard deviation of approximately half the mean fiber 
diameter. Additionally, nearly all SEM images showed bead-free nanofiber morphology, 
indicating relatively good polymer stream stability (Figure 2.1 (a and b)).  As shown in 
the SEM images, the fibers appeared to be smooth, and while there were some small 
changes in diameter, the fiber morphology was generally consistent along the length of 
the sampled fibers. The quantitative and qualitative observations were indicative of 
stable electrospinning conditions.   
It has been reported that free OLA may influence pre-osteoblast functionality when 
present at higher concentrations and in serum-free conditions [142]. However, the 




OLA would influence the behavior of entire cell population in the culture because of the 
presence of a range of fatty acids in the serum used with the culture medium. However, 
it should be acknowledged that some MSCs, particularly osteoblasts and 
osteoprogenitors, may be influenced by OLA via peroxisome proliferator activated 
receptors (PPARs) [136, 143]. There is evidence that activation of PPAR and possibly 
PPAR may direct differentiation of mature progenitor cells towards osteoblasts rather 
than adipocytes [142-144]. Furthermore, several other studies have shown the role of 
PPAR in directing osteoprogenitor cells into adipocytes rather than osteogenic lineages 
[145, 146]. Our current research results are insufficient to draw any conclusions about 
the effects of OLA, but its potential for influence should be noted. Moreover, this may 
present additional possibilities for adding osteoconductive design features into nanofiber 
scaffolds, and studies in our laboratory are now directed towards evaluating the effects 
of OLA on MSC differentiation. 
Synthetic bone tissue scaffolds have the capacity to regenerate functional bone 
tissue at the site of serious injury (i.e. critical-sized defects or non-union fractures). 
Marrow stromal cells migrate to the injury site in a carefully orchestrated manner, 
controlled by chemokines, growth factors and ECM proteins [147, 148]. Initial attachment 
of MSC is especially critical for long-term stability and differentiation of the cells; thus, 
the capacity for nanofiber scaffolds to support MSC adhesion and proliferation was 
evaluated using live cell fluorescence staining and an MTT assay.  
Cells on nanofiber scaffolds formed noticeably more colonies than on control 
surfaces after 1 and 4 days of initial culture, which was reflected in the significant 
differences in cell coverage (Figure 2.2 (a and b); Figure 2.3 (a), and Figure 2.2 (c and 
d); Figure 2.3 (a)). It is worth noting that these measured differences in cell coverage 




culture (as discussed later in this section). After 7 days, cells on control surfaces had 
spread out individually, but there were still only small clusters of a few cells rather than 
the more highly populated colonies observed on nanofiber scaffolds (Figure 2.2 (e and 
f)). The cell coverage was not calculated after 4 days since differences on nanofiber 
scaffolds and control surfaces were visually very clear, and cells on nanofiber scaffolds 
were near confluence at many locations.   
Cell viability was investigated using a commercially available MTT assay, which 
measures the total intracellular mitochondrial activity in the cell population. A 
measurement of cell viability is important in evaluating the capacity for a scaffold to 
support initial cell proliferation. In order to deliver a scaffold containing cells with 
therapeutic potential, the colony must demonstrate good viability. As expected, our 
results suggest that cells are viable on both nanofiber scaffolds and control surfaces for 
up to 4 days in culture (Figure 2.3 (b)). Further, the cell viability on nanofiber scaffolds 
was significantly greater than on control surfaces at both time points.  
Cell viability, as assessed by the MTT assay, was measured after 1 and 4 days of 
culture since this time period is associated with the log-phase growth of the cell 
population. MTT provides complimentary information to calcein-AM staining because the 
MTT assay differentiates between levels of metabolic activity of a cell population rather 
than a snapshot of cells that retain the activated calcein AM molecule. A visual 
inspection of colonization, as well as a measurement of cellular metabolism and 
spreading provided information on the ability of cells to populate these nanofiber 
scaffolds. Based on these two analyses, the nanofiber scaffolds demonstrated a greater 
ability to support MSC populations than the control surfaces.  
In order to visualize morphological changes in MSCs, SEM images were taken after 




indicating that the MSCs preferentially adhere, spread and aggregate on nanofiber 
scaffolds as compared to control surfaces (Figure 2.4). After 1 day of culture, the cells 
on both control surfaces and nanofiber scaffolds were relatively spherical in morphology 
(Figure 2.4 (a and b)). However, some cells on nanofiber scaffolds showed a small 
degree of spreading. After 4 days of culture, most of the cells maintained a spherical 
appearance on control surfaces, whereas on nanofiber scaffolds the cells have spread 
out and show filopodia extending towards adjacent cells (Figure 2.4 (c and d)). While 
there were a few tightly clustered colonies on nanofiber scaffolds, it was more common 
to see few cells in close proximity to other cells without tight clustering. After 7 days of 
culture, most cells have spread out on both control and nanofiber scaffolds, but the 
overall cell population was noticeably less dense on control than on nanofiber scaffolds 
(Figure 2.4 (e and f)). No infiltrated cells were observed under SEM after 1 and 4 days 
of culture, though several cells were observed to be beneath the top layer of fibers after 
7 days in culture. 
A successful bone scaffold must demonstrate support for enhanced bone formation, 
including organic and inorganic components of natural tissue. ALP is a key component 
of bone matrix vesicles because of its role in the formation of apatitic calcium phosphate 
[149], and it is an early indicator of immature osteoblast activity [39]. Although cells in 
several tissues—liver, kidney, placenta, etc.—generate the enzyme, elevated levels of 
ALP in bone tissue typically are observed several days prior to neo-mineralization and 
during the initial phase of bone matrix deposition [39, 150]. The ALP patterns observed 
over the 3 week experimental period for nanofiber scaffolds were consistent with the 
previously established patterns in osteoblast-like populations cultured on other nano-
structured materials [87, 137, 138]. Figure 5 shows ALP activity normalized to total 




colorimetric ALP assay results at 1 week of culture showed no statistical difference 
between nanofiber scaffolds and control surfaces, and standard deviations for both the 
nanofibers and smooth surfaces were nearly equal to the value of the mean, indicating 
large inter-specimen variability. After 2 weeks, significant differences were evident 
between the nanofiber scaffolds and control surfaces; and after 3 weeks, cells on 
nanofiber scaffolds produced considerably increased levels of ALP, with statistical 
significance over the control surfaces. 
Mineralization patterns were qualitatively examined by SEM/EDS, Alizarin calcium 
staining and von Kossa staining. Figure 2.6 shows digital images of the stained surfaces 
(calcium (red) on top, phosphate (brown) stain on bottom) along with SEM images after 
3 weeks of culture on both nanofiber and control surfaces. SEM images showed surface 
mineralization in the form of discrete nodules in greater abundance than control 
surfaces. Calcium and phosphate minerals were stained in the form of Alizarin red 
(calcium) and von Kossa (phosphate), respectively, and nanofiber scaffolds showed 
greater speckled patterns, indicative of mineral nodule formation, than the control 
surfaces which were much more homogeneous (Figure 2.6 (a and b)). SEM images 
show that the cells on nanofiber scaffolds had colonized and the surface is covered with 
dense cell populations. In these cell colonies, filopodia were observed to be in direct 
contact with neighboring cells as well as with nanofiber architecture. On nanofiber 
scaffolds, cells were frequently and clearly visible underneath the top layer of nanofibers.  
After 2 weeks of culture in osteogenic media, nanofiber scaffolds exhibited frequent 
mineralization in the form of spherulites (Figure 2.6 (d)), and while there was evidence 
of some mineralization on smooth PCL surfaces, it was less noticeable and there were 
very few spherulites (Figure 2.6 (c)). Further, cells on nanofiber scaffolds were 




the cells were more widely spread and formed colonies on nanofiber scaffolds as 
compared to control surfaces. After 3 weeks in osteogenic media, mineralization on 
nanofiber scaffolds had further increased (Figure 2.6 (f)). Notable amounts of calcium 
and phosphate were observed on control surfaces, though the SEM images revealed a 
lower amount of cell spreading and mineralization (Figure 2.6 (e)). Nanofiber scaffolds 
had substantial calcium phosphate deposition and cells were frequently observed in 
intimate contact with the deposited mineral. As with the 2 week culture, there was 
greater cell density on the nanofiber scaffold surface than on the control surface, and 
quite a few cells were observed beneath the top layer of fibers. EDS scans detected 
Ca:P mineral deposits on nanofiber scaffolds with greater abundance than on control 
surfaces.  Figure 2.7 shows an elemental compositional map of mineral deposit on 
nanofiber scaffolds after 3 weeks of culture. EDS is not ideal for making precise about 
the stoichiometry of calcium phosphates on gold-coated samples since gold will 
confound the phosphorus K-line signal, but these atomic spectra are clear indicators that 
cells have deposited calcium phosphates on the surface.   
OP and OC were imaged using immunofluorescent staining. OP is a non-
collagenous bone matrix protein that is believed to be an important factor in cell 
adhesion to mineralized tissue, as well as playing a role in regulating bone remodeling in 
a manner dependent on its degree of phosphorylation and sulfation [151, 152]. It has a 
region rich in aspartic acid with high affinity for mineralization as well as several integrin-
binding sequences [153-155]. OC is highly specific to bone tissue and generally 
produced towards the end of new bone matrix deposition [156]. It is also thought to play 
a role in modulating mineralization as it has glutamic acid-rich regions with strong 
binding affinities to both Ca2+ and hydroxyapatite [154, 155]. Immunofluorescence 




available OP and OC primary antibodies and a FITC-conjugated secondary antibody 
after 3 weeks in osteogenic media.  
Several differences were apparent between the nanofiber and control surfaces.  
Immunofluorescent labeling demonstrated greater amounts of both bone matrix proteins, 
OP and OC, on the nanofiber scaffold surface (Figure 2. (8c and d)) compared to that 
on control surfaces (Figure 2.8 (a and b)). One particularly interesting finding on the 
nanofiber scaffolds was that both stains were observed within the scaffold because of 
strong backlighting of nanofiber features, indicating not only infiltration into the scaffold, 
but also active production of bone matrix protein by the infiltrated cells (Figure 2.8 (e 
and f)). Since we are using an immunofluorescent staining technique, our results 
suggest that the backlighting is not due to fluorescent residues, but due to marker 
proteins secreted by the differentiated cells. The microscope used for this study was not 
ideal for quantifying infiltration depth, but combined with repeated observations of 
infiltrated cells by SEM, there is clear evidence supporting the potential of these 
scaffolds for three-dimensional bone tissue formation.  From an architectural standpoint, 
the nanofiber scaffolds are more desirable than the control surfaces for several reasons, 
including increased cell adhesion, proliferation, differentiation and ECM production [68, 
69, 157, 158]. Bulk PCL has a very slow degradation rate [109], but with the very large 
surface-area-to-volume ratio characteristic of nanofibers, the degradation rate for the 
nanofiber scaffolds could be tuned to approximate more closely the remodeling rate of 
bone. The porosity of nanofiber scaffolds also allow for cell infiltration and three-
dimensional mineralization.  
Evidence suggesting cellular infiltration was observed via SEM, and 
immunofluorescent images showed strong signals of bone matrix protein synthesis from 




conducted in vitro as well as in vivo to evaluate the ability of nanofiber scaffolds to 
entrap cells and integrate with the bone. 
 
2.6. Conclusions 
Given the wide range of potential bone graft recipients, a synthetic source of bone 
tissue scaffolds that enhances bone formation holds the potential for a substantial 
positive clinical impact. This work demonstrated the ability to produce consistent 
nanofibers by incorporating an organosoluble, non-toxic fatty acid salt using an 
electrospinning process. In addition, nanofiber scaffolds supported greater adhesion and 
proliferation by MSCs as compared to control surfaces. In osteogenic conditions, ALP 
activity, mineralization, and osteocalcin and osteopontin production were also greater 
compared to control surfaces.  The performance of these nanofiber scaffolds 
demonstrates that studies examining osteogenic design factors must control for 
architecture independently of any soluble or insoluble design factor. 
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3.1 Chapter Summary 
Incorporation of biomimetic hydroxyapatite nanoparticles into polymer nanofibers can be 
accomplished with electrospinning.  In this work, hydroxyapatite (HAp) nanoparticles, 
were incorporated into poly(-caprolactone) (PCL) nanofibers at two concentrations – 
1% and 10% of the solid weight.  Rat bone marrow stromal cells were seeded on the 
scaffolds and their initial response was evaluated for 7 days in maintenance media, and 
then for the 3 following weeks in osteogenic media.  Results showed differences in 
metabolic activity and cell coverage at days 1 and 4 while in maintenance media.  
However, by day 7, cell coverage values and live cell images showed very similar 
colonies on all three scaffolds.  In osteogenic conditions, the 10% HAp scaffolds 
exhibited significantly increased ALP assay levels at week 3, though not at weeks 1 and 
2.  Osteopontin and Osteocalcin immunofluorescent microscopy revealed a trend that 
both mineralized scaffolds had greater amounts of both proteins though qPCR and 
results indicated the opposite trend for osteopontin.  Additionally, type I collagen 
expression was decreased on HAp scaffolds.  These results indicate that cells are 
clearly interpreting the mineralization in the nanofibers, even at just 1% w/w, and the 






3.2 Motivation and Aims 
Synthetic tissue scaffolds for bone regeneration have taken several design 
approaches with the intent of enhancing bone formation by marrow stromal cells 
(MSCs).  In order to enhance progenitor cell differentiation, biomimetic designs have 
been explored that enhance cell functionality once progenitors are differentiated into 
specialized phenotypes such as osteoblasts.  Soluble signals such as growth factors or 
cytokines have been shown to enhance osteoblastogenesis [159-162] by activating cell 
surface receptors.  Additionally, immobilizing and presenting whole extracellular matrix 
(ECM) proteins such as fibronectin or short adhesion peptides such as RGS have both 
been shown to enhance proliferation and phenotypic behaviors [163, 164].  Previous 
studies have shown modestly-enhanced osteoblast phenotypic behaviors by 
incorporating hydroxyapatite (HAp) or other calcium phosphate phases to bulk of the 
scaffolds as an immobilized signal [32, 37], but unlike growth factor delivery, the 
mechanisms which induce changes in the cell phenotypic behaviors have yet to be 
clarified.  The goal of this chapter is to fabricate HAp/PCL composite nanofibers by 
electrospinning, and then examine changes to key osteoblast behaviors. 
Hydroxyapatite (Ca5(PO4)3OH) (HAp) is the primary inorganic phase of bone 
tissue, and in Haversian bone it resides in gaps at the ends of type I collagen fibrils with 
a well-controlled crystallographic orientation [165].  As new bone is forming and existing 
bone is remodeled, osteoblasts secrete bone matrix vesicles (BMVs) containing Ca-rich 
fluid and phosphatases such as alkaline phosphatase (ALP) [49, 149] that release 
phosphates.  HAp integration into type I collagen comprises a bone subunit, and mature 
bone tissue is further strengthened by its hierarchical architecture [166-168].  Cells are 
capable of binding to collagen through several integrin heterodimers [169], but binding to 




171].  Because HAp is an important component of natural bone tissue, it is an attractive 
design feature for synthetic bone tissue scaffolds as a means of more closely mimicking 
the natural tissue composition [37, 172-176].  Thus we aim to produce HAp/PCL 
composite nanofibers by embedding HAp nanoparticles in PCL nanofibers. 
HAp is a substantially more hydrophilic molecule than PCL.  To prevent 
agglomeration of HAp nanoparticles during electrospinning process, one previous study 
included 12-hydroxystearic acid into the polymer solution as a surfactant.[38]    Adding a 
surfactant allowed HAp to be more homogenously distributed throughout the PCL 
nanofibers, which in turn avoided disruptions to the fiber scaffold morphology (i.e. 
microbeads).  In this study, we have used oleic acid (OLA) sodium salt to prevent 
agglomeration of HAp nanoparticles.  OLA is an organosoluble fatty acid salt that is non-
toxic to cells.  It is a known agonist to peroxisome proliferator–activator receptors 
(PPARs), a class of nuclear receptors [177].  PPARs have been associated with a wide 
range of cellular functions and processes [145, 178-180].  In order to account for 
possible effects of PPAR, the concentration as held constant for all scaffolds 
In this chapter, PCL scaffolds with two different concentrations of HAp were 
fabricated using electrospinning process.  In order to account for any potential effects of 
OLA on PPARs, the concentration was kept constant for all scaffolds.  The effects of 
modulating HAp concentration were examined on marrow stromal cells cultured in 
maintenance media through seven days, and then in osteogenic media for three weeks.  
The effect of increasing the concentration of HAp in PCL scaffolds was investigated in 
terms of marrow stromal cell adhesion and proliferation in maintenance conditions and 






3.3.1 Fabrication and characterization of HAp-PCL nanofiber scaffolds 
Nanofiber scaffolds were fabricated using electrospinning process.  A polymer 
solution was prepared by dissolving of 12% w/w PCL (Sigma) with 3% oleic acid sodium 
salt in a solvent mixture of 3:1 chloroform and methanol (Sigma), and 0%, 1% and 10% 
w/v of hydroxyapatite (HAp) nanoparticles (size<200 nm, Sigma) were homogeneously 
mixed into this solution to achieve different concentrations of HAp in the scaffolds.  A 
high-voltage power supply (Gamma High Voltage) was applied between 18-21 kV on a 
blunt-tip catheter positioned 4-4.5‖ from a grounded collector.  The polymer solution was 
fed to the catheter tip by a syringe pump (Kent Scientific) at 1.8-2.1 mL/hr and the 
scaffolds were deposited on the grounded collector. 
In order to examine the morphology of the nanofiber scaffolds, they were sputter-
coated with 10 nm of gold and imaged under high magnification using a field-emission 
scanning electron microscope (SEM, JEOL JSM-6500F) followed by an EDX spatial 
elemental mapping examination.  Instrument aperture and probe current were adjusted 
to give a dead time of 15–20%. Surfaces were analyzed for 5 min at 5–15 kV and a 
magnification of 100–5000x to provide a complete profile of the different elements 
present. Spatial element mapping was performed by grouping pixels with similar atomic 
spectra. Fiber diameters were measured using SEM image analysis software.  Ten 
measurements were made on each scaffold with nmin = 30 and size distribution 
histogram was plotted. 
Thermal characterization of the nanofiber scaffolds was performed to determine 
the effect of electrospinning process on polymer crystallinity and thermal stability.  Digital 
scanning calorimetry (DSC, TA Instruments DSC 2920) was used to determine the 


















where Hm,sample is the enthalpy of melting of the nanofiber scaffold and Hm,std is the 
enthalpy of melting of 100% crystalline PCL (Hm,std = 139 J/g) [174].  Thermogravimetric 
analysis (TGA, TA Instruments TGA 2950) was used to measure the change in mass as 
a function of temperature. The nanofiber scaffolds were heated from 25oC to 700oC at 
10oC/min and the weight loss was measured.  In both the thermal analysis techniques, 
polymer pellets that had not been subjected to electrospinning process were used as 
controls, and are noted as ―Source PCL‖. 
 
3.3.2 Rat marrow stromal cell culture 
Marrow stromal cells (MSC) were isolated from male Wistar rats (Rattus 
norvegicus) supplied by Harlan Sprague Dawley, Inc (separate time points, unmixed cell 
populations).  Limbs were aseptically removed from recently euthanized animals.  Soft 
tissue was removed and the bones were briefly stored in cold PBS before isolating cells.  
Metaphyseal ends of the bones were removed to expose the bone marrow cavity.  In a 
50 mL conical tube, marrow was repeatedly flushed with maintenance media (-MEM 
with 10 % fetal bovine serum (FBS, Sigma) and 1 % penicillin/streptomycin (pen/strep, 
Sigma)) using 10 mL syringes with 18 and 25 gauge needles.  Media containing cells 
and debris was filtered with a 70μm nylon filter into a clean tube.  Cells were counted 
using a hemocytometer before seeding.  Control (smooth PCL) and electrospun 
scaffolds (NF and MN) (surface area approximately 0.7 cm2) were sterilized by exposing 




substrates were then washed twice with warm PBS followed by warm culture media prior 
to MSC seeding.  Cells were seeded on scaffolds in a 24-well plate at a density of 1 
million per well. Cultures were incubated at 37.0 °C and 5 % CO2 for the duration of the 
study.  Half of the media was changed at day 4.  On Day 7, the media was replaced with 
osteogenic differentiation media (-MEM with 10% fetal bovine serum, 1% penicillin-
streptomycin, 10-8 M dexamethosone, 50 g/mL ascorbic acid, 8 mM -
glycerolphosphate).  Media was changed every 2 days for up to 3 weeks of culture.  All 
scaffolds were cultured and assayed in triplicate at each time point specified (i.e. 1, 2, or 
3 weeks post-differentiation, n=6). 
 
3.3.3 MSC adhesion and proliferation on HAp-PCL nanofiber scaffolds 
After 1, 4, and 7 days of culture in maintenance media, cell responses to the 
scaffolds were investigated through cell adhesion, and viability (mitochondrial activity) 
viability was examined after 1 and 4 days.  Cells adhesion was investigated using the 
live cell stain calcein AM (Invitrogen) (ex: 485 nm, em: 530 nm).  Calcein AM can 
penetrate live cell membranes, where the AM is cleaved and the resulting calcein 
molecule fluoresces green.  The cells were incubated in 2 mM of calcein AM in PBS for 
45 min and were imaged with a fluorescence microscope (Zeiss) with appropriate filters. 
Images were analyzed (ImageJ, NIH) to compute the percent area covered by live cells 
for comparison with the cell viability assay. 
Cell viability was measured after 1 and 4 days of culture (log phase growth) using 
a commercially available MTT assay kit (Sigma).  Adhered cells were incubated at 37 °C 
for 3 hours in a (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) 
solution. Mitochondrial dehydrogenases of viable cells cleave the tetrazolium ring, 




solvent with 10% (volume) Triton-X.  The optical density (OD) of the solvent is 
proportional to the mitochondrial activity of the cells on the surface.  OD was measured 
at 570 nm using a spectrophotometer (FLUOstar Omega; BMG Labtech, Durham NC).  
Background absorbance at 690 nm was subtracted from the measured absorbance.   
 
3.3.4 MSC differentiation on HAp-PCL nanofiber scaffolds 
MSC responses to the electrospun scaffolds were investigated 1, 2, and 3 weeks 
after providing the cells with osteogenic differentiation media.  A colorimetric alkaline 
phosphatase (ALP) assay, total protein assay, quantitative polymerase chain reaction 
(qPCR), and immunofluorescent staining were used to evaluate the cell responses to 
nanofibrous architecture with varying concentrations of HAp nanoparticles.   
In order to quantify intracellular ALP production at weeks 1, 2, and 3, cells were 
lysed by incubation in CellLytic® (Sigma) at room temperature, and the lysate was used 
for ALP and BCA total protein assay.  ALP activity was measured using a commercially-
available colorimetric assay kit (Quantichrome™ BioAssay Systems), and the 
manufacturer‘s protocol was followed[181].  Briefly, ALP catalyzes the reaction removing 
the phosphate from p-nitrophenolphosphate (p-NPP), thus yielding p-nitrophenol, and 
the p-nitrophenol concentration is measured by the absorbance at 405 nm.  The same 
lysate was also used to determine the total intracellular protein content using a 
commercially available BCA (bicinchoninic acid) assay (Pierce Biotechnology).  The 
absorbance of the solution was measured using a plate reader at a wavelength of 570 
nm and was converted to protein content using an albumin standard curve. All of the 
ALP data was normalized with the total protein content to account for changes in number 




The expression levels of several key bone-related genes were measured with 
qPCR after 1, 2 and 3 weeks of culture.  Messenger RNA (mRNA) was purified from 
other nucleic acids (rRNA, tRNA, DNA) using an RNeasy extraction kit (Qiagen).  
Genomic DNA (gDNA) contamination was avoided by degrading any remaining gDNA 
with DNaseI (Fermentas).  Complimentary DNA (cDNA) template was generated from 
mRNA with a first-strand synthesis kit (Fermentas), and both the DNaseI and reverse 
transcriptase enzymes were thermally inactivated after their respective steps according 
to the manufacturer‘s protocols.  cDNA was stored in at -80oC until further use.  For PCR 
reactions, primers were either designed as documented below, or were purchased as a 
forward-reverse primer mix (Qiagen).  Custom-designed primers (Table 3.1) were 
validated by running gel electrophoresis with the product to ensure that the amplicon 
length matched the predicted length, and by performing a melt curve step at the end of 
real-time quantitative PCR (qPCR) to verify the presence of a single amplicon. 
 
The amplicon from successful reactions was purified using the ethanol 
precipitation method [182].  Finally, purified amplicon concentrations were measured 
with a spectrophotometer (Nanodrop, Thermo Scientific), and standards were then 










Amplicon length: 159 bp 




  After three weeks in osteogenic media, scaffolds were removed and immuno-
labeled for osteopontin and osteocalcin.  Cells were fixed with 3.7% paraformaldehyde in 
PBS solution and permeabilized with a 1% Triton-X in PBS solution.  Blocking serum of 
40 g/mL of trypan blue (Sigma) and 100 g/mL of bovine serum albumin in PBS was 
used to reduce non-specific antibody binding.  After rinsing and blocking, the scaffolds 
were incubated in either an osteopontin primary antibody (1:100 in PBS, V-19 purified 
goat polyclonal antibody of mouse origin, Santa Cruz Biotechnology) or an osteocalcin 
primary antibody (P-18 purified goat polyclonal antibody of mouse origin, Santa Cruz 
Biotechnology) for one hour.  After an additional blocking step and PBS wash, the 
scaffolds were then incubated in a FITC-conjugated secondary antibody (1:200 donkey 
anti-goat IgG, Santa Cruz Biotechnology) for 45 minutes in the dark.  The scaffolds were 
rinsed once more before being imaged under 470 nm excitation wavelength using a 
fluorescence microscope (Zeiss). 
 
3.3.5 Statistical analysis 
All test and control substrates were cultured and assayed in triplicate at each 
time point specified. The experiments were conducted in duplicate using different 
animals as the MSC source for each study.  The data was pooled from the studies using 
different cell sources.  All the statistics presented here as a mean +/- standard deviation.  
A general linear model of ANOVA with a Tukey adjustment for multiple comparisons was 
used to determine the effects of treatment (HAp concentration), time (days or weeks 
where noted), and the interaction of treatment by time.  Any data point with a student 
residual value greater than 3 was deemed an outlier, and the ANOVA was re-calculated 




0.05 was considered significant.  For significant effects, assay values at each were 
compared using a two-way t-test and p-values were reported. 
 
3.4 Results 





Figure 3.1 – SEM (A and B) and EDX (C-F) images of 10% (A, C, E) and 1% (B, D, F) HAp 
scaffolds.  Atomic spectra showed next to the corresponding EDX images 
In this study, PCL nanofiber scaffolds were fabricated with 0%, 1%, and 10% 
HAp nanoparticles embedded within the nanofibers.  The scaffolds were examined 
under SEM to examine the scaffold morphology and fiber diameters.  The results here 
showed continuous nanofibers for all three scaffolds with no observable nanoparticle 
agglomeration or fiber distortion due to the presence of HAp (Figure 3.1 (A, B)).  There 
was a measurable, though small decrease in the mean fiber diameter for scaffolds with 
10% HAp (Figure 3.2 (A)), from 360 nm to 290 nm.  However, for all three scaffold 
types, >80% of the fibers measured within 200-500 nm in diameter (Figure 3.2 (B)).  
HAp-free scaffolds were examined in Chapter 2 and SEM images may be viewed in that 
chapter. 
   Further, EDX was used demonstrate the distribution of HAp nanoparticles in the 
PCL nanofibers.  The two spectral images for each scaffold type show a difference 





Figure 3.2 – Fiber diameter histogram (A) and mean fiber diameters (B) for 
all three scaffolds. 
 
Figure 3.3 - % crystallinity (A) and mass loss (B) measured by DSC and 
TGA respectively.   
uncoated interior (Figures 3.1 (C and D)).  Both show the presence of calcium and 
phosphorus, but only the surface spectra show gold.  Additionally, the homogenous 
appearance of spectral maps strongly suggests that HAp nanoparticles are relatively 
evenly distributed throughout the polymer nanofibers.   









TGA was analyzed over a range of temperatures associated with PCL mass loss, but not 
HAp loss [174], and the mass lost during analysis was PCL.  Source PCL was included 
to describe any changes to the polymer due to electrospinning process and HAp 
nanoparticles.  DSC did not measure any significant difference between the three 
scaffolds (HAp-free, 1% HAp, and 10% HAp) as well as the source PCL (Figure 3.3 











Figure 3.4 – Metabolic activity levels measured by an MTT assay 
samples (Figure 3 (B)).  All three scaffolds and the source PCL showed slightly lower 
mass losses than anticipated, and there was no significant difference between 1% and 
HAp-free scaffolds.  However, each material was displaced from its anticipated value by 
1-2%, which may have simply been due to measurement uncertainty.  Overall, between 
the SEM and EDX images, there is strong evidence that HAp nanoparticles are relatively 
homogenously distributed throughout the nanofibers, and TGA provides strong evidence 
that the desired amounts of 1% and 10% wt HAp nanoparticles were incorporated into 
PCL nanofibers.  
 
3.4.2 MSC adhesion and proliferation on HAp-PCL nanofiber scaffolds 
  Fresh marrow stromal cells were harvested from rat long bones and seeded onto 
scaffolds at a density of 1x106 cells/scaffold.  The cells cultured in maintenance media 
free of differentiation factors, and the metabolic activity was measured after 1 and 4 days 
of culture using MTT assay, and live cells were stained with calcein AM after 1, 4, and 7 
days of culture.  The metabolic activity was measured using a commercially-available 
MTT assay kit, and days 1 and 4 were chosen because this period is associated with 







10% HAp and 





Figure 3.5 – Fluorescent images of live cells stained by calcein AM on HAp-free, 1% HAp, 
and 10% HAp scaffolds at days 1, 4, and 7 
 
Figure 3.6 – Live cell coverage of scaffold 
surfaces measured at days 1, 4, and 7 
and the effect of HAp was significant (p=0.007) 
  Calcein AM was used to image 
live adhered cells on the scaffold 
surfaces. The fluorescence microscopy 
images were used to calculate the 
scaffold surface area covered by live 
cells.  The images (Figure 3.5) show 
similarities for cells on the different 
scaffolds.  At day one, cells on all three 
scaffolds clearly had adhered in large 





Figure 3.7 – ALP activity measure at weeks 1, 2, and 3 
compared to later days.  By day four, cells were larger though possibly less densely 
populated.  At this point, a measurable difference between cells on HAp-free scaffolds 
and 1% and 10% scaffolds was apparent (Figure 3.6). However, by day 7 the cells were 
large and densely populated on all scaffolds and there was no significant difference in 
cell coverage and the fluorescent images showed strong similarities between scaffolds.  
 
3.4.3 MSC differentiation on HAp-PCL nanofiber scaffolds 
  In order to evaluate differences in the osteogenic capacity of HAp-PCL scaffolds, 
the cells were differentiated with glucocorticoids at day seven.  After 1, 2, and 3 weeks in 









(qPCR).  Alkaline phosphatase (ALP) activity and total protein were measured using 
commercially-available, colorimetric assay kits and ALP was normalized with the amount 
of total protein.  ALP activity was very low on all three scaffolds after week one (Figure 
3.7).  At week two, all three scaffolds supported marked increases in ALP, although 
there were no significant differences.  By week three, cells on 10% HAp produced 





Figure 3.8 – RhoA expression measured at weeks 1, 2, and 3 
significantly different from 1% HAp scaffolds.  Overall, the effect of time (weeks) was 
highly significant and the interaction of HAp and week was nearly significant (p=0.07).   
 Quantitative polymerase chain reaction (qPCR) was used to precisely measure the 
levels of gene expression for several key genes related to osteoblast behaviors.  The 
expression level for each gene was normalized with respect to RPL13A, a housekeeping 
gene that encodes for the 60s ribosomal subunit protein, L13A.  The log10, normalized 
expression levels were then used for an ANOVA with an adjustment for multiple 
comparisons. 
  RhoA is a small GTPase associated with actin cytoskeletal reorganization and it has 
shown to be key for osteoblast behaviors [183-185].  RhoA expression levels were 
significantly affected by HAp concentration, week, and the interaction of HAp with week 





1% HAp.  It 
is important 
to note that 
the 
expression 
levels only show statistical significance within a time-point at week three.  At week three, 
cells on 1% and 10% HAp scaffolds had down-regulated RhoA expression whereas cells 






Figure 3.9 – Casein Kinase II expression measured at weeks 1, 2, and 3 
  Casein Kinase II (CKII) is a serine/threonine kinase that has been shown to be 
the major relevant kinase of bone phosphoproteins such as osteopontin [186-188].  The 
effects of HAp, 
week, and the 
interaction of 





over a relatively 
narrow range of normalized expression levels (Figure 3.9).  Both HAp and week had the 
effect of decreasing the expression levels, but it should be noted that in week one, 10% 
HAp supported the greatest expression of CKII which was significant relative to cells 1% 
HAp scaffolds.  At week two, expression levels were very similar, and then at week 
three, cells on HAp-free scaffolds expressed CKII at levels significantly greater than cells 
on either HAP scaffold.   
  Osteopontin (OP) is a bone matrix phosphoprotein secreted by both osteoblasts 
and osteoclasts [170, 187, 189].  Both main effects (HAp and week) and the interaction 
effect were all significant within a narrow range (Figure 3.10).  At week one, cells on 
10% HAp expressed greater levels than cells on 1% HAp scaffolds, and at week three, 
cells on HAp-free scaffolds expressed significantly greater levels of OP than cells on 
either HAp scaffold.  Overall, cells on HAp-free scaffolds expressed the greatest amount 





Figure 3.10 – Osteopontin (OP) expression measured at weeks 1, 2, and 3. Star 
indicates statistically significant difference (p<0.05) 
 
Figure 3.11 – Type I collagen expression at weeks 1, 2, and 3.  Star indicates 
statistically-significant difference (p<0.05) 
 
 Collagen 








osteoblasts during bone synthesis.  As with other genes, both main effects and the 
interaction effect were significant though the differences were over a small range of 
expression levels (Figure 3.11).  Overall, cells on HAp-free scaffolds expressed the 
greatest amounts of collagen I, followed by cells on 1% HAp and then 10% HAp 
scaffolds.  Cells on HAp-free scaffolds also had sustained gene expression through 
three weeks 
whereas cells 












Figure 3.12 – Immunolabeled OP and OC after 3 weeks 
in osteogenic media.  Scale bars are 50 m 
  At week 3, cells were 
immunolabeled for either 
osteopontin or osteocalcin and 
then viewed under a 
fluorescence microscope.  The 
images revealed presence of 
both bone matrix proteins on all 
the scaffolds (Figure 3.12).  
Many small depositions were 
visible on scaffold surfaces, and 
larger aggregates (>50 m) were 
also observed, more so on 10% 
HAp scaffolds.   In general, greater amounts of both bone matrix proteins were evident 
on the 10% HAp scaffolds as compared to 1% and HAp-free scaffolds.   
 
3.5 Discussion 
The aim of this study was to determine the effects of including and varying the 
amount of HAp nanoparticles in polymer nanofibers would affect cell adhesion and 
proliferation as well as osteoblast phenotypic behaviors.  In order to assess these cell 
responses, HAp-free scaffolds were fabricated along with scaffolds with 1% w/w HAp or 
10% w/w HAp nanoparticles.  To prevent agglomeration of hydrophilic HAp 
nanoparticles in a solution with organic solvents and hydrophobic PCL, a surfactant was 
included in the electrospinning solution.  Incorporation of HAp nanoparticles in polymer 
nanofibers has been successfully demonstrated in prior research studies[190] with 




agglomeration [190].  By contrast, these nanofibers were fabricated with oleic acid 
(OLA), an 18-carbon, w-9 monounsaturated fatty acid.  Kim et al (2006) used a different 
fatty with the sole function being fabricating mineralized nanofibers without 
agglomeration,[38] but OLA may enhance bone formation through activation of fatty acid 
receptors [143, 191].  Thus, the concentration of OLA was kept as a constant level for all 
scaffolds used in this study 
 Scaffold characterization by SEM showed that differences between HAp-free and 1% 
HAp scaffolds were nominal while both scaffolds were statistically different from 10% 
HAp scaffolds.  It is important to note that the mean fiber value shifted from ~360 nm for 
HAp-free scaffolds to 290 nm for 10% HAp scaffolds (Figure 3.2 (B)).  However, looking 
at the fiber diameter histogram (Figure 3.2 (A)), all three scaffolds have their median 
value in the same diameter range (300-399 nm), and >80% of the fiber diameters fall 
within 200-500 nm.  Furthermore, differences over this low range of fiber diameters have 
been shown to be of negligible importance for osteoblasts and fibroblasts, a phenotype 
sharing a very similar transcriptome to that of osteoblasts [192], on similar 
nanostructured materials [140, 193].  Given that additional variables in the system here 
include surface chemistry and mechanical stiffness due to HAp nanoparticles, it is 
reasonable to conclude that the differences in fiber diameter are not important to the 
cellular responses. 
 Fracture repair involves multiple overlapping healing phases involving wide range of 
processes for cell recruitment and signaling [194-196], ECM production [197-200], and 
then ECM remodeling [201-203].  Fundamental to each of these processes is the ability 
for cells to adhere and proliferate in the repair area.  By imaging live cells with a calcein 
AM fluorescent stain, measuring their coverage area, and measuring metabolic activity 




between cell coverage and MTT was strong; with the measured cell coverage values 
closely matching MTT absorbance values at days one and four (Figures 3.4 & 3.6).  The 
initial days after cell seeded are associated with log phase population growth and 
proliferation on tissue scaffolds, and MTT absorbance values are used as relative 
measures of overall metabolic activity for the cell population.  Metabolic expenditures 
during this time are likely to go towards proliferation, though it is clear from the 
fluorescent stain that substantial cell spreading occurred (cytoskeletal formation and 
reorganization) during the first week.  It should be noted that by day seven, cell coverage 
values were very similar, which is important because osteogenic differentiation factors 
were added to the cell media at that point.  This finding is consistent with recent 
literature examining nanofiber scaffolds containing HAp nanoparticles [175].  
 In order to evaluate the effects of HAp on bone matrix production for each of the three 
weeks in osteogenic media, a colorimetric ALP assay along with qPCR for five genes.  
After three weeks in osteogenic media cells were also immunolabeled for two bone 
matrix proteins, OP and OC.  Of the five genes, two bone matrix genes (OP, Col1) were 
selected to determine changes in bone matrix production along with the ALP colorimetric 
assay, two genes (CKII and RhoA) were selected that would illustrate cell adaptations 
due to HAp nanoparticles, and one housekeeping gene (RPL13A) was used to 
normalize expression values.   
 Alkaline phosphatase (ALP) is a key enzyme in bone matrix vesicles that cleaves 
organic phosphate esters, thus supplying mineral nucleation sites with phosphate ions 
[149, 204, 205].  Its expression profile is typically associated with a peak during early 
differentiation of progenitor cells into immature osteoblast phenotypes, and then 
production tapers off as osteoblast cells either mature into osteocytes or undergo 




separating the effects of weeks), the effect of weeks is significant and the interaction of 
HAp and weeks is borderline significant (p=0.07).  Due to the large temporal changes in 
ALP expression, it is valuable important to look at the interaction of HAp and weeks than 
it is to look at HAp on its own.  The final time point, week three, shows that ALP is most 
abundant on 10% HAp scaffolds, and the t-test at that time point is significant over HAp-
free scaffolds.  Previous studies examining ALP expression on polymer-mineral 
composite scaffolds used more homogeneous cell populations and also found a similar 
trend of small increases in ALP activity on mineralized scaffolds [35, 37, 175, 207].  
Since these studies used several different polymers and demonstrated similar results, 
this nominal overall increase in ALP activity through three weeks on synthetic polymer-
HAp scaffolds can be considered to be a predictable result. 
 Collagen I (Col1) and osteopontin (OP) are organic components of bone tissue.  OP 
is part of the family of non-collagenous proteins (NCPs) referred to as SIBLING (Small 
Integrin-Binding LIgand, N-Linked Glycoprotein) proteins [208].  Col1 is the major 
organic phase of bone and makes up ~30% of bone mass.  Both proteins are expressed 
by osteoprogenitors, pre-osteoblasts and osteoblasts, though OP is expressed in greater 
levels across multiple phenotypic phases while Col1 is expressed highest by matrix-
producing osteoblasts and then is down-regulated in a similar manner as ALP [39].  The 
expression levels for both Col1 and OP were similar with HAp-free scaffolds supporting 
the greatest overall expression levels, followed by 10% and then 1% scaffolds (Figures 
3.10 & 3.11).  Down-regulation of Col1 has been identified as an indicator that matrix-
producing osteoblasts are continuing on their maturation path.  This is somewhat in 
contradiction to ALP activity levels which may be expected to approximate Col1 
expression levels [39].  However, the overall expression level of Col1 was still very high 




 By examining expression levels for two enzymes, casein kinase II (CKII) and RhoA, 
that play important roles in regulating bone formation and osteoblast behaviors, potential 
mechanisms influencing differences in cell responses to PCL-HAp scaffolds may be 
identified.  CKII is a serine/threonine kinase that is believed to be responsible for most of 
the physiologically-relevant phosphorylation for bone phosphoproteins such as OP [186]. 
It phosphorylates the side-group on serine residues, and the degree of phosphorylation 
of bone matrix proteins such as OP is believed to up or down-regulate local bone 
remodeling behavior by osteoblasts and osteoclasts [171, 209].  RhoA, a small GTPase 
associated with key osteoblast behaviors as well as actin cytoskeletal remodeling.  
Recent findings have identified RhoA as not only a regulator or osteoblastogenesis[184, 
185], but also of mechanotransduction [183] and apoptotic regulation specifically for 
osteoblasts [210]. 
   The qPCR results show only nominally higher RhoA expression levels by cells on 
HAp-free scaffolds at week one, then equal expression levels at week two before 
significantly greater expression levels by cells on HAp-free scaffolds at week three 
(Figure 3.8).  Similarly, CKII expression levels were differentially regulated with 
statistically significance overall.  At week one, 10% HAp scaffolds supported the highest 
expression, while week two levels were highly similar on all scaffolds, and week three 
levels were highest on HAp-free scaffolds (Figure 3.9).  The overall effect of HAp was 
significant for both proteins, and HAp-free scaffolds supported the greatest overall 
expression.  Since both RhoA and CKII are dependent on phosphorylation for to switch 
between active and inactive states [183], further studies focused on changes in 
activation of both enzymes will be necessary.  However, RhoA is subject to proteosomal 
degradation through ubiquitination [211], and osteoblasts have been shown to 




differential RhoA expression levels are a strong indicator that RhoA should be explored 
as a means to explain differential osteoblast behaviors in response to PCL-HAp 
nanofiber scaffolds.   
 The qPCR data for these four genes points to several important conclusion regarding 
mineralized polymer scaffold design. Most notably, the greatest expression levels for 
OP, CKII, and RhoA occurred on HAp-free scaffolds, followed by 10% HAP, and then 
1% HAp (Figures 3.8, 3.9, and 3.10).  Col1 deviated from this trend with HAp-free 
scaffolds supporting the greatest expression, followed by 1% HAp and then 10% HAp 
(Figure 3.11).  This demonstrates that cells are very sensitive to changes in extracellular 
mineralization, and bone-related gene expression may be moderately suppressed with 
low HAp concentrations within the nanofibers, as evidenced on 1% scaffolds.  Aside 
from Col1, gene expression moderately increased between cells on 1% and 10% HAp 
concentration.  However, the expression levels supported by 10% HAp scaffolds were 
still less than HAp-free scaffolds and closer in value to 1% scaffolds.   
 This is the first study to report Col1 and CKII expression levels by qPCR, and one of 
only two that have examined gene expression for bone matrix proteins [175].  However, 
the similarity of ALP activity levels between this and previous studies indicates that these 
gene expression values can be received with confidence [37, 207].  Overall, the data 
indicates that the cells sense mineralized, fibrous architecture in their extracellular 
environment.  This chemistry and architecture causes the cells to reduce their bone 
matrix production, as indicated by the Col1 and OP expression levels.  Additionally, the 
similar expression patterns for CKII and OP suggest that it is unlikely that OP would be 
phosphorylated to different degrees between treatments.  Thus, the mineralization within 






 PCL nanofiber scaffolds were fabricated to be HAp-free, or have either 1% or 10% 
HAp nanoparticles within the PCL nanofibers.  Material characterization methods verified 
that the desired nanofibrous morphology and compositions were achieved, and a 
difference in mean fiber diameter was unlikely to significantly affect the cell population.  
There were difference in the initial levels of metabolic activity, but by day seven, the cell 
populations, as measured by coverage, were very similar.  Once in osteogenic media, 
cells on 10% HAp scaffolds supporting the greatest ALP levels at week three, though 
there were no differences at weeks one or two.  qPCR data demonstrated that key 
genes were differentially regulated.  Type I Collagen (Col1) expression levels decreased 
in a manner dependent on HAp concentration, while OP, CKII, and RhoA depended 
more on the presence than concentration of HAp.  The presence of HAp in these PCL 
nanofiber scaffolds caused a decrease in OP, CKII and Col1 expression.  These results 
show that cells are highly sensitive to changes in extracellular mineralization, and 
understanding how cells sense this change would be highly beneficial to synthetic 
scaffold design.  Future studies will investigate activation for RhoA and CKII and also 
evaluate these scaffolds in vivo to validate the results in the absence of glucocorticoids.   
 
3.9 Future Work 
 This chapter showed that incorporating HAp into PCL nanofibers causes an 
increase in ALP activity at one time-point and a decrease in type I collagen expression.  
These results were consistent with several previous studies examining polymer-HAp 
nanofibers for osteogenesis.  Chapter 5 addresses the in vivo work that was performed 
to evaluate the efficacy of incorporating HAp into nanofibers as a means of increasing 




combined with the observation that cells are sensitive to HAp nanoparticles in nanofibers 
even at only 1% w/w suggests that the cells have a sensitive mechanism by which they 
sense mineralization in their extracellular surroundings.  Much of the literature pertaining 
to cell adhesion in bone tissue has focused on OP, OC, and osteonectin (ON), but 
changes in integrin expression have not yet been examined.  Integrin expression has 
been shown to change with changes between polymer and metallic substrates [163], 
and these changes should be investigated with PCL-HAp nanofiber constructs.  
Understanding the molecular tools by which cells sense this mineralization may be 
important to future scaffold designs, and also for understanding bone tissue 
maintenance.   
 The inclusion of 10% HAp in nanofiber scaffolds is likely to change the 
mechanical properties of the scaffold.  Recently, the signaling pathway with through 
which mechanical stiffness is sensed in cells was linked with activating RhoA [183].  This 
is a significant finding because activating RhoA has been shown to be necessary for 
osteoblastogenesis [184, 185] and RhoA activity can regulate pro-survival or apoptosis 
pathways [210, 213].  An investigation into the change in PCL-HAp scaffold stiffness, 
and the effects on RhoA activity and downstream substrates would be a significant 
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4.1 Chapter summary 
 In this chapter, the effects of oleic acid (OLA) released from PCL nanofiber scaffolds 
on cell behaviors was investigated.  PCL-OLA scaffolds were fabricated to contain either 
1% or 5% w/w OLA, and OLA-free scaffolds were produced by incubating 1% OLA in 
methanol for 24 hours.  The scaffolds were characterized in terms of their fiber diameter, 
and changes in composition and crystallinity were measured by thermogravimetric 
analysis (TGA) and differential scanning calorimetry (DSC).  Additionally, scaffold mass 
loss due to the presence of an esterase was measured.  In order to evaluate the 
response of marrow stromal cells (MSCs), fresh marrow stromal extracts were seeded 
onto the scaffolds, and cell adhesion and metabolic activity were measured during the 
initial week after seeding.  After one week, cells were provided with osteogenic media.  
Intracellular alkaline phosphatase (ALP) activity and calcium deposition were measured 
colorimetrically, and gene expression levels for osteopontin (OP), RhoA, and three 
peroxisome proliferator-activator receptor isoforms were measured with quantitative 
polymerase chain reaction (qPCR).  After three weeks, OP and osteocalcin (OC) were 
immunolabeled for fluorescent microscopy.  Scaffold characterization results showed 
that the three scaffolds contained similar fiber diameter distributions, and the crystallinity 
of the materials were all similar to source PCL.  TGA measured a significantly different 
composition for 5%, but not 1% OLA scaffolds.  OLA had a significant effect on both 
metabolic activity and cell coverage, decreasing both measures in significant manners.  
However, in osteogenic conditions, cells on 5% OLA scaffolds showed significantly 
greater ALP activity, calcium deposition, and OP accumulation throughout three weeks 
in osteogenic media.  QPCR expression data showed that cells differentially expressed 
OP with moderate significance.  RhoA was not differentially expressed, and only PPAR 




cells on 5% OLA scaffolds showed the greatest levels of osteoblast phenotypic 
behaviors, and the OLA is likely acting through PPARs on the 5% scaffolds.   
 
4.2 Motivation and Aims 
 Designing bone tissue scaffolds with soluble design factors remains a very active 
area, with the greatest attention paid to growth factors and short peptides [160, 214-
218].  When these signals are presented to progenitor cells, they will activate endocrine 
signaling pathways [160, 162, 219], thus directing the progenitor cells towards 
osteoblastogenesis.  One area that has not yet received significant attention is the role 
of fatty acids in osteoblastogenesis.  Fatty acids are an abundant part of the normal 
human diet, and variations in fatty acid species within particular tissues  have been 
linked to diseases such as obesity [220], atherosclerosis [221], heart disease [222], and 
cancer [223-225].  Many fatty acids are agonists for peroxisome proliferator-activator 
receptors (PPAR), a class nuclear membrane receptors that has been associated with a 
wide range of cellular functions [136].  Cells express three isoforms of PPARs; , , and 
 and each isoforms contains a DNA-binding domain so that the activated PPAR (as a 
heterodimer with a retinoic acid receptor) can bind to gene promoter regions [226].  
Many cellular fate processes including differentiation of progenitor cells into adipocytes 
rather than osteoblasts have been positively correlated to differential PPAR expression 
and activation[143, 145, 191, 227-229].   
 Oleic acid (OLA) is an organosoluble, -9, monounsaturated fatty acid that has been 
shown to increase osteoblast phenotypic behaviors such as ALP expression in serum-
free conditions [143].  It has also been shown to permit immortalized osteoblast cell 
proliferation in serum-supplemented conditions [230].  Fatty acids such as OLA are 




medullary adipocytes [230].  OLA has been shown to have the greatest affinity for 
PPARand lowest for PPARa phenotypic marker for adipocytes [177].  In fact, steroid 
hormones used to treat non-skeletal endocrine diseases have been scrutinized for their 
potential inhibitory effects on osteoblasts due to cross-talk between PPARs and other 
families nuclear receptors [231-234].  Whereas PPAR activation has been widely 
accepted as an effective pathway for adipocytogenesis, PPAR activation continues to 
be studied as a suspected mechanism for osteoblastogenesis [144, 235, 236].  The aim 
of this chapter is to demonstrate that OLA, a fatty acid with strong preferential binding to 
PPAR, will enhance osteoblast phenotypic behaviors and induce differential expression 
of PPARs. 
 
4.3 Materials and methods 
4.3.1 Fabrication & Characterization of Nanofiber Scaffolds 
Nanofiber scaffolds were fabricated by electrospinning 80,000 molecular weight PCL 
polymer (Sigma) solution (12% w/w) with either 1% or 5% w/w of OLA-sodium salt 
(Sigma).  PCL and OLA were dissolved in a solvent mixture of 3:1 (volume ratio) 
chloroform:methanol  (Sigma) and loaded into a glass syringe (Hamilton, Gastight 1010).  
The polymer solution was fed to a blunt-tip catheter by a syringe pump (Harvard 
Apparatus) at a rate of 1.8-2.1 mL/hr.  A high-voltage power supply (Gamma High 
Voltage Research, model ES30P-10W/DAM) was used to apply voltage in the range of 
18-21 kV to the blunt-tip catheter that was positioned 4-4.5‖ from the grounded collector 
plate.  
In order to fabricate control (OLA-free) nanofiber scaffolds, 1% OLA scaffolds were 
incubated in methanol for 24 hrs to leach out the OLA-sodium salt.  1% OLA scaffolds 




detect the presence or absence of sodium which characteristic to OLA.  XPS was 
performed with a PHI-5800 spectrometer using a monochromatic Al K X-ray source 
(1486.6 eV).  The measurements were taken at an electron takeoff angle of 45o from the 
normal sampling surface.  The binding energy scale was calibrated prior to analysis by 
the Au4f7/2 peak at 83.9 eV, and the linearity was verified by the Cu3p1/2 and Cu2p3/2 
peaks at 76.5 and 932.5 eV respectively.  Survey scans were performed between 10 eV 
and 1100 eV with pass energy of 187.5 eV.  All spectra were referenced by setting the 
C1s peak to 285.0 eV to compensate for residual charging effects.  
In order to examine the morphology of the nanofiber scaffolds and determine the 
fiber diameter, they were sputter-coated with 10 nm of gold and imaged under high 
magnification using a field-emission scanning electron microscope (SEM, JEOL JSM-
6500F). Fiber diameters were measured using SEM image analysis software.  Ten 
measurements were made on each scaffold with nmin=30 and size distribution histogram 
was plotted. 
Thermal characterization of the nanofiber scaffolds was performed to determine the 
effect of electrospinning process on polymer crystallinity and thermal stability.  Digital 
scanning calorimetry (DSC, TA Instruments DSC 2920) was used to determine the 
polymer crystallinity in different nanofiber scaffolds. The scaffolds were heated from 5oC 
















where Hm,sample is the enthalpy of melting of the nanofiber scaffold and Hm,std is the 
enthalpy of melting of 100% crystalline PCL (Hm,std = 139 J/g) [174].  Thermogravimetric 




a function of temperature. The nanofiber scaffolds were heated from 25oC to 700oC at 
10oC/min and the weight loss was measured.  In both the thermal analysis techniques, 
polymer pellets that had not been subjected to electrospinning were used as controls. 
 
4.3.2 PCL/OLA scaffold mass loss due to esterase activity  
 Changes in the mass of the PCL/OLA nanofiber scaffolds was investigated in 
conditions with and without an esterase.  10 mm discs of OLA-free, 1% OLA, and 5% 
OLA  scaffolds were cut using a sterile biopsy punch, weighed, and then the scaffolds 
were sterilized by washing in ultra-pure H2O (R=18.2 M) and PBS, with 10 min UV 
exposure during each wash.  Scaffolds were then incubated at 37oC and 100% humidity 
in 1 mL of either PBS or PBS with 8 IU of lipase from pseudomonas capacia [110, 237].  
At days 1, 4, and 7, scaffolds were removed from PBS, rinsed with diH2O and dried in a 
desiccator overnight.  Their masses were weighed again and the percent of mass lost 
was calculated.  The number of scaffolds at each time point in PBS-enzyme was N=3, 
whereas the number of scaffolds in PBS at each time point was N=2.   
 
4.3.3 Isolation and Culture of Marrow Stromal Cells 
Marrow stromal cells (MSC) were isolated from male Wistar rats (Rattus 
norvegicus) supplied by Harlan Sprague Dawley, Inc. Animal protocol was approved by 
Colorado State University Animal Care and Use Committee.   This committee is in 
compliance with the NIH Guide for Care and Use of Laboratory Animals.  Limbs were 
aseptically removed from the recently euthanized animals.  Soft tissue was removed and 
the bones were briefly stored in cold PBS before isolating cells.  Metaphyseal ends of 
the bones were removed to expose the bone marrow cavity.  In a 50 mL conical tube, 
marrow was repeatedly flushed with culture maintenance media (α-MEM (Hyclone) with 




using 10 mL syringe with 18 and 25 gauge needles.  Media containing cells and debris 
was filtered with a 70μm nylon filter into a clean conical tube.  Cells were counted using 
a hemocytometer before seeding on nanofiber scaffolds. 
Prior to cell seeding, nanofiber scaffolds, denoted as OLA-free, 1% OLA, and 5% 
OLA, (surface area approximately 0.7 cm2) were sterilized under uv light for 60 min while 
in DI water.  The substrates were then washed twice with warm PBS followed by warm 
culture media.  The cells were seeded on the nanofiber scaffolds in a 24-well plate at a 
density of 1 X 106 cells per well. The cultures were incubated at 37oC and 5 % CO2 for 
the duration of the study.  Half of the media was changed after 4 days of culture.  After 7 
days of culture, the media was replaced with osteogenic differentiation media 
(maintenance media plus 10-8 M dexamethosone (Sigma), 50 g/mL ascorbic acid 
(Sigma), 8 mM -glycerophosphate (Sigma)).  Subsequent media changes were done 
every 2 days for up to 3 weeks of culture.  
 
4.3.4 MSC Adhesion and Proliferation on PCL/OLA Nanofiber Scaffolds 
MSC response to the nanofiber scaffolds was investigated through cell adhesion, 
viability (mitochondrial activity), and morphology after 1, 4, and 7 days of culture. The 
scaffolds were removed from the culture media and rinsed twice in PBS prior to further 
analysis. 
Cells adhesion was investigated using a live cell stain, Calcein AM (Invitrogen) (ex: 
485 nm, em: 530 nm).  Calcein AM can penetrate live cell membranes, where the AM is 
cleaved and the resulting calcein molecule fluoresces green.  The cells were incubated 
in 2 M of calcein AM in PBS for 45 min and were imaged with a fluorescence 
microscope with a 470 nm filter. Images were analyzed using ImageJ (NIH) software to 




MSC viability on nanofiber scaffolds was measured after 1 and 4 days of culture (log 
phase growth) using a commercially available MTT assay kit (Sigma).  The adhered cells 
were incubated at 37oC for 3 hrs in a (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) solution. Mitochondrial dehydrogenases of viable cells cleave 
the tetrazolium ring, yielding purple formazan crystals.  Formazan crystals were then 
dissolved in the MTT solvent containing 10% (volume) Triton-X (Sigma). The optical 
density (OD) was measured at 570 nm using a plate reader (BMG Labtech, FLUOStar 
Omega).  The background absorbance at 690 nm was subtracted from the measured 
absorbance.  The OD is proportional to the mitochondrial activity of the live proliferative 
cells on the scaffold surface.  
 
4.3.5 MSC Differentiation on PCL/OLA Nanofiber Scaffolds 
MSC differentiation on nanofiber scaffolds was investigated after 1, 2 and 3 weeks of 
providing the cells with osteogenic differentiation media (i.e. after 1 week in maintenance 
media).  Alkaline phosphatase (ALP) activity, calcium deposition, surface phosphate 
deposition, and non-collagenous bone matrix protein deposition were used to assess the 
differences in cell phenotypic behavior due to the presence of OLA in the nanofiber 
scaffolds.  The scaffolds were removed from the culture media and rinsed twice in PBS 
prior to further analysis.  
To determine the alkaline phosphatase (ALP) activity on nanofiber scaffolds, the 
adhered cells were lysed with Cell Lytic™ (Sigma) solution for 1 hr.  A commercially 
available ALP colorimetric assay kit (Quantichrome™ BioAssay Systems) was used to 
quantify ALP concentration in the lysate.  Briefly, ALP catalyzes the reaction of p-
nitrophenolphosphate (p-NPP) to p-nitrophenol and phosphate.  p-nitrophenol was 




concentration of ALP in the lysate.  ALP concentration was calculated using the 
guidelines provided by the manufacturer.  Further, the same lysate was also used to 
determine the total intracellular protein content using a commercially available BCA 
(bicinchoninic acid) assay (Pierce Biotechnology).  The absorbance of the solution was 
measured using a plate reader at a wavelength of 570 nm and was converted to protein 
content using an albumin standard curve. All the ALP data was normalized with the total 
protein content to account for changes in number of cells present on each surface.   
In order to visualize the phosphate deposition on the nanofiber scaffold surface, von 
Kossa staining technique was used.  The scaffolds were rinsed twice with cacodylate 
buffer and then immersed in 2% paraformaldehyde (Sigma) (w/v) in cacodylate buffer for 
10 min.  They were then rinsed with de-ionized water and then a 1% silver nitrate 
solution (Sigma) in DI water was added.  The scaffolds were incubated at room 
temperature for 20 mins, allowing the phosphate and silver nitrate to react to form a 
brown precipitate.  The reaction was spontaneously stopped by rinsing the scaffolds 
three times with DI water.  Scaffolds were dried in a desiccator and digital images of 
stained surfaces were captured. 
Cell morphology on nanofiber scaffolds was investigated using SEM.  The cells were 
immersed in a fixing solution (3% glutaraldehyde (Sigma) with 0.1 M sucrose (Sigma) 
and 0.1 M sodium cacodylate (Polysciences) in DI water) for 45 min, rinsed in a buffer 
solution (fixing solution without glutaraldehyde), and then dehydrated in increasing 
concentrations of ethanol (30, 50, 70, 90, and 100 %) for 10 min each.  After dehydration 
the scaffolds were immersed in hexamethyldisilazane (HDMS, Alfa) for 10 min and were 
air-dried. The scaffolds were stored in a desiccator until further SEM characterization. 
Prior to SEM imaging, the scaffolds were sputter-coated with 10 nm layer of gold.  The 




energy-dispersive X-ray spectroscopy (EDX) probe (Thermo Electron, Noran system) to 
the SEM.  EDX was used to detect mineralization (presence of calcium and phosphorus) 
on the scaffold surfaces.  Instrument aperture and probe current were adjusted to give a 
dead time between 15 – 20 %.  Scaffold surfaces were analyzed for 20 mins at 10 – 15 
kV and a magnification of 1000 to 5000x to provide a complete profile of different 
elements present.  Spatial element mapping was performed by grouping pixels with 
similar atomic spectra. 
Gene expression for osteopontin, RhoA, PPAR, PPAR, and PPAR were 
investigated 1, 2 and 3 weeks after providing the cells with osteogenic differentiation 
media (i.e. after 1 week in maintenance media).  The scaffolds were removed from the 
culture media and gently rinsed twice in PBS prior to lysate incubation.  Messenger RNA 
(mRNA) was purified from using an mRNA purification kit (RNeasy, Qiagen).  Genomic 
DNA (gDNA) contamination was avoided by degrading any remaining gDNA with 
DNaseI (Fermentas).  Complimentary DNA (cDNA) template was generated from mRNA 
with a first-strand synthesis kit (Fermentas), and both the DNaseI and reverse 
transcriptase enzymes were thermally inactivated after their respective steps according 
to the manufacturer‘s protocols.  cDNA was then stored at -80oC until further use.  For 
PCR reactions, primers for OP were designed as documented below, and all others 
were purchased as a forward-reverse primer mix (Qiagen) where noted.  Custom-
designed primers (Table 4.1) were validated by running gel electrophoresis with the 
product to ensure that the amplicon length matched the predicted length, and by 
performing a melt curve step at the end of real-time quantitative PCR (qPCR) to verify 





The amplicon from successful reactions was purified using the ethanol precipitation 
method [182].  Finally, purified amplicon concentrations were measured with a 
spectrophotometer (Nanodrop, Thermo Scientific), and standards were then diluted with 
DNase-free water for use in calculating the copy number from test qPCR reactions. 
After 3 weeks in osteogenic media, the cells on scaffolds were immuno-labeled for 
osteopontin (OP) or osteocalcin (OC). The cells were fixed by immersing in 3.7% 
paraformaldehyde (w/v) in PBS for 10 mins followed by permeabilization in a 1% Triton-
X in PBS solution for 10 mins.  A blocking serum of 40 g/mL of trypan blue (Sigma) and 
100 g/mL of bovine serum albumin (Sigma) in PBS was used to reduce non-specific 
antibody binding.  After rinsing and blocking, scaffolds were incubated in either an OP 
primary antibody (1:100 in PBS, V-19 purified goat polyclonal antibody of human origin, 
Santa Cruz Biotechnology) or OC primary antibody (1:100 in PBS, P-18 purified goat 
polyclonal antibody of mouse origin, Santa Cruz Biotechnology) for 1 hr.  After an 
additional blocking step and PBS wash, scaffolds were then incubated in FITC-
conjugated donkey anti-goat IgG (1:100 dilution, Santa Cruz Biotechnology) for 45 
minutes in the dark.  The scaffolds were rinsed once more before imaging under 470 nm 
excitation wavelength using a fluorescence microscope.   
 
4.3.6 Statistical analysis 
All nanofiber scaffolds (OLA-free, 1% OLA, and 5% OLA) were cultured and 
assayed in triplicate at each time point specified. The experiments were conducted in 
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mass-loss, a one-way ANOVA examining the effects of day, OLA, and enzyme was 
performed.  For cell studies, a one-way ANOVA with a Tukey adjustment for multiple 
comparisons was performed to determine the significance of OLA (concentration within 
the polymer nanofibers), time (weeks or days as indicated), and the interaction of OLA 
and time (the effects of time on a measurement, separated by treatment).  Statistical 
significance was defined as p<0.05.  Values with a student residual >3 were deemed 
outliers and removed, and the statistical analysis was performed again.  For treatments 
which were found to be significant, statistical groupings for t-tests within the same time-
point are reported, with different symbols indicative of a p-value < 0.05.  All statistics are 
presented here as a mean +/- standard deviation. 
 
4.4 RESULTS 
4.4.1 Fabrication & Characterization of Nanofiber Scaffolds 
In this study, PCL nanofiber scaffolds were fabricated with either 1% or 5% OLA in 
PCL polymer solution using electrospinning technique and the scaffolds were 
characterized using SEM to evaluate their nano-architecture (Figure 4.1 (a, b)).  OLA-
free scaffolds were confirmed to be free of the OLA-sodium salt molecule by XPS (data 
not shown).  The nanofiber scaffolds with different OLA concentrations have insignificant 
differences in their mean fiber diameters (Figure 4.1 (c)), and the fiber diameter 
distribution histogram revealed a possible mild positive skew for both OLA 
concentrations (Figure 4.1 (d)).  Further, all the scaffolds occasional had very large 
diameter nanofibers, up to and sometimes exceeding 1 μm in diameter, however, > 85% 
of the fibers were in the range of 150-350 nm. Since OLA-free scaffolds were fabricated 
by leaching out the salt from 1% OLA scaffolds, their fiber diameters were represented 





Figure 4.1 – SEM images of 1% OLA (A) and 5% OLA (B) scaffolds 
with the fiber diameter characteristics (C and D) 
Thermal characterization of the nanofiber scaffolds was performed to determine the 
effect of electrospinning process on polymer crystallinity and thermal stability.  DSC 
revealed no significant differences in the crystallinity of the polymer between scaffolds 
containing different concentrations of OLA.  For nanofiber scaffolds (OLA-free, 1% OLA 
and 5% OLA), the PCL crystallinity was similar to that of source PCL pellets (not-
electrospun; control samples) that had not been subjected to electrospinning.  The 
methanol treatment used to produce OLA-free scaffolds also had no significant effect on 
the crystallinity of 
the polymer (Figure 
4.2 (a)).  However, 
TGA revealed 
significant 
differences in mass 
loss for 5% OLA 
scaffolds as 
compared to other 
scaffolds and 
control substrate 
(Figure 4.2 (b)).  Further, there were insignificant differences in mass loss for OLA-free 
scaffolds, 1% OLA scaffolds and control substrate. 
 





Figure 4.2 – Scaffold characterization of 
% crystallinity by DSC (A) and % mass 
loss by TGA (B).  Star indicates 
significant difference (p<0.05) 
 
Figure 4.3 – Mass loss of PCL/OLA scaffolds after 1, 4, and 7 days.  Star indicates statistically-
significant difference (p<0.05) 
 In order to evaluate the effects of an 
esterase on the degradation behavior of 
PCL/OLA nanofibers scaffolds, the scaffolds 
were weighed and placed in either PBS or PBS 
with lipase of pseudomonas capecia an 
enzyme with esterase activity.  After 1, 4, or 7 
days the scaffolds were removed, rinsed, dried, 
and weighed again to calculate the mass loss.  
The presence of the enzyme had a clear effect 
on mass loss, which resulted in a highly 
significant (p<0.0001) overall main effect 
(Figure 4.3). Neither the effect of day nor OLA 
were significant at the 95% level, though the 
effect of day (p=0.09) would be significant at 
the 90% confidence level.  Within each time point, there were several statistically-
significant differences, though only at day 1 was there a difference in mass loss between 
scaffolds – OLA-free and 5% OLA – in PBS without enzyme.  All other comparisons 
were insignificant.  Generally the mean value of mass loss for scaffolds in the enzyme 





Figure 4 – MTT assay results for days 1 and 4.  Symbols indicate statistically-like grouping 
(p>0.05) 
with no enzyme.  Thus there may have been loss due to OLA elution which was 
accelerated due to bulk erosion, but the differences in mass loss between scaffolds in 
the enzyme were likely driven by a loss of PCL mass.  
 
4.4.3 MSC Adhesion and Proliferation on Nanofiber Scaffolds 
MSCs were seeded on different nanofiber scaffolds in a 24 well plate at a density of 
1 X 106 cells/well and their response was investigated through cell adhesion, viability 
(mitochondrial activity), and morphology after 1, 4, and 7 days of culture.  A 
commercially available MTT assay was used to measure the overall metabolic activity 
for the cell population on different nanofiber scaffolds after 1 and 4 days of culture since 
this is the time-period associated with log-phase growth of cells (Figure 4.4).  
 The results show that the cells are viable on all the scaffolds after 4 days of culture.  
Statistically, both OLA and the interaction of OLA by day were highly significant, but the 
effect of day was not significant.  The main effect of OLA was a clear decrease in 
metabolic activity with an increase in OLA concentration within the polymer nanofibers.  
T-tests revealed significant differences in cell viability after 1 day of culture between 1% 
and 5% OLA scaffolds, while neither scaffold had a significant difference from the OLA-
free (control) scaffolds.  However by day 4, OLA-free scaffolds supported the greatest 
levels of metabolic activity and both 1% and 5% OLA scaffolds supported similar, 




The live, adhered cells were stained with calcein AM and imaged using a fluorescence 
microscope after 1, 4 and 7 days of culture (Figure 4.5).  The images show a clear trend 
of decrease in cell coverage with increases in OLA concentration within the polymer 
nanofibers, and this trend is more prominent with the progression of time.  Across the 
three time points, cells on 5% OLA scaffolds were much less spread out than those on 
OLA-free scaffolds.  By contrast the cells on 1% OLA scaffolds appear to be spreading 
in a similar way as those on OLA-free scaffolds, however there appear to be fewer cells 
compared to both the 5% OLA and OLA-free scaffolds.  
In order to quantify this trend and calculate the percentage of scaffold area covered 
by live cells, the fluorescence microscopy images were analyzed using ImageJ software.  
The cell coverage data confirms the visual observation that increasing OLA 
concentration within the polymer nanofibers decreases the cell coverage area (Figure 
 
Figure 5 – Calcein AM staining of live cells at days 1, 4, and 7.  10x magnification, scale 





Figure 4.6 – Cell coverage measurements at days 1, 4, and 7.  ‘*’ indicates 
statistically-significant difference (p<0.05) 











nanofiber scaffolds.  The cells on OLA-free scaffolds showed a dramatic increase in the 
coverage after 7 days of culture, whereas the cells on 1% OLA scaffolds had moderate 
increases in coverage followed by the cells on 5% OLA scaffolds had effectively no 
increase in cell coverage for up to 7 days of culture.   
 
4.4.4 MSC Differentiation on PCL/OLA Nanofiber Scaffolds 
MSC differentiation into osteoblasts on nanofiber scaffolds was investigated after 1, 
2 and 3 weeks of providing the cells with osteogenic differentiation media (i.e. after 1 
week in maintenance media). ALP activity was measured using a colorimetric assay and 
the results were normalized with total intracellular protein content measured using a 
BCA assay.  The normalized results show significantly higher ALP activity on 5% OLA 
scaffolds as compared to 1% OLA and OLA-free scaffolds (Figure 4.7), with OLA, week, 
and the interaction of OLA by week all at highly significant p-values.  Not only did the 





Figure 4.7 – ALP data for 1, 2, and 3 weeks in osteogenic media.  
Symbols indicate statistically-like grouping (p>0.05) 
 
Figure 4.8 – Calcium deposition on scaffolds measured by colorimetric 
assay after 1, 2, and 3 weeks in osteogenic media.  ‘*’ denotes statistical 
difference (p<0.05) 
through culture 
period of three 
weeks shows a 
sustained 
increase in the 
activity from week 
to week that 
neither 1% OLA 
nor OLA-free 
scaffolds 
supported.   
Calcium deposition due to mineralization by osteoblasts was quantified using a 
colorimetric assay.  The results show increased calcium deposition on 5% OLA scaffolds 
as compared to 1% OLA and OLA-free scaffolds (Figure 4.8) The effects of OLA, week, 
and the 
interaction of 
OLA by week 
were all 
significant.   
However, similar 
to ALP activity 
after 3 weeks of 
culture, the cells 






Figure 9 – SEM images of cells and/or mineralization on OLA-free (A-C), 1% OLA (D-F), 
and 5% OLA (G-I) scaffolds.   
had greatest levels of calcium deposition followed by OLA-free and 1% OLA scaffolds.  
SEM imaging coupled with EDX and von Kossa (phosphate) staining was used to 
examine the MSC differentiation and bone matrix mineral deposition on scaffold surfaces 
(Figure 4.9). All three scaffolds supported cell adhesion and Ca-P mineralization for up 
to 3 weeks of culture in osteogenic media.  The scaffolds showed an inhomogeneous 
pattern of cell adhesion with certain regions without any cells (Figure 4.9 (g)) while 
others nearly completely covered with dense cell colonies (Figure 4.9 (f)).  Generally, 
1% OLA scaffolds appeared to contain less mineralization than the OLA-free and 5% 
OLA scaffolds, as evaluated by SEM and EDX. This was particularly evident at weeks 1 
and 2 (Figures 4.9 (a, b, d, e, g, h)).  Long, very thin fibrils were visible only in the cases 
of large (greater than ~10 m) mineral deposits (Figure 4.9 (d) and 4.10)).  These fibrils 





Figure 10 –SEM (A and D) and EDX (B and E) images of 
mineralization at 2000x (A and B) or 15,000x (D and E) 
magnification.  Atomic spectrum of red phase from EDX images 
also picture (C and F) 
Phosphate staining 
for scaffolds revealed 
dark, heterogeneously 
distributed pattern 
throughout the scaffold 
surfaces (Figure 4.11).  
It was difficult to 
observe any qualitative 
differences between 
scaffolds since the staining showed up quite dark, though this dark stain is indicative of 
substantive mineralization on all scaffolds.  EDX confirmed that the mineral deposits 
observed under SEM were Ca-P, and these deposits were abundantly distributed on 
scaffold surfaces.  The size of Ca-P deposits varied over a very large size range; some 
were 10-50 m in their largest axis (Figure 4.10 (b)), while other Ca-P appeared as 
small spherulites <1m (Figure 4.10 (a)).  SEM images revealed that the cells appear to 
be in intimate contact with mineral deposits on the scaffold surface (Figure 4.10 (a, c, f, 
h)).  It should be noted that Ca-P mineralization was evident even in regions without any 
cells (e.g Figure 4.9 (g)).  Further, EDX also detected mineral deposits immediately 
underneath the dense cell colonies suggesting infiltration of the cells in the scaffold 
porous architecture.  The atomic spectra obtained from the EDX data was used to 






Figure 4.11 – Digital images of phosphate (von 
Kossa) stains 
 
Figure 4.12 – Normalized expression levels for osteopontin (OP).  
Expression was normalized with respect to RPL13A.  Star indicates 
statistical difference (p<0.05) 
Osteopontin is an important 
component of bone ECM, and it is 
secreted by both osteoblasts and 
osteoclasts [170, 187, 189].  The 
expression profile of OP by cells on 
all three scaffolds was fairly 
dynamic, with an expression peak at 
week two (Figure 4.12).  The main 
effect of OLA was moderately 
significant (p=0.09), and the trend 
suggests that overall expression levels increase as OLA increases.  The interaction 
effect of OLA by week was highly significant (p=0.001), and mean expression values by 
cells on OLA scaffolds were greater than those on OLA-free scaffolds for weeks one and 
two.  In individual t-tests, there was a significant difference at week one between 
expression levels on OLA-free and 5% OLA scaffolds.  Overall this suggests that 
differences in 
expression levels 
suggested in the 
ANOVA model 









Figure 4.13 – Immunofluorescent stains of OP and 
OC.  Magnification is 10x, scale bar is 50 m 
 
Figure 4.14 – Expression levels of RhoA for each week, presented as the 
log of normalized values 
OP and osteocalcin (OC) 
deposition on scaffolds were visualized 
using immunofluorescent staining 
(Figure 4.13) The immunofluorescent 
images revealed that OP appeared in 
the greatest abundance on 5% OLA 
scaffolds after 3 weeks of culture, and 
OC appeared in relatively equal 
abundance across all three scaffolds.  
The images revealed presence of both 
bone matrix proteins on all the 
scaffolds with similar patterns as that of mineralization.   
 RhoA is a small GTPase associated with actin cytoskeletal reorganization, and 
several studies have demonstrated crucial roles for RhoA in osteoblast behaviors, 
including osteoblastogenesis [183-185].  Expression levels were relatively consistent 
across all three weeks (Figure 4.14), and the ANOVA showed no significant difference 





Figure 4.15 – Expression levels of PPAR for each week.  Data 
presented as the log of normalized expression.  Star indicates 
statistically significant difference (p<0.05) 
was significant and expression peaked at week two, which was evident in the main 
effects plot.  Most importantly, OLA had no significant effect on RhoA expression by cells 
in osteogenic media. 
 Expression levels for the three isoforms of PPARs were examined at each week.  
PPAR expression showed highly significant (p<0.001) changes due to OLA, with a 
clear decreasing trend with increase in OLA concentration (Figure 4.15).  Additionally, 
the interaction effect of OLA by week was also significant, indicating that changes in 
expression levels from week to week were different depending on the OLA content of the 
scaffolds.  The 
interaction plot shows 
that for weeks one and 
two, expression levels 
on both OLA scaffolds 
change in similar 
manners.  Further, 
between weeks two and 
three, cells 1% OLA and 
OLA-free showed a 
similar change in expression levels.  Interestingly, t-tests showed that statistically 
significant (p<0.05) differences existed between expression levels on OLA-free and 1% 
OLA scaffolds at weeks one and two, while expression levels on 5% OLA scaffolds were 
different from the other two at week three.  It should be noted that a t-test between OLA-
free and 5% OLA scaffolds was borderline yielded a p-value of 0.1, though this is not 





Figure 4.16 – Expression levels of PPAR for each week.  Data 
presented as the log of normalized expression 




scaffolds has a 
significant effect 
on PPAR 
expression levels.   
 Expression 
levels for PPAR 
were also affected by OLA in the nanofibers..  Both main effects, OLA and week, were 
significant, but the interaction effect was not significant (Figure 4.16).  Unlike PPAR, 
there were no significant differences within each time point.  This indicates that the 
significant differences observed in the main effect of OLA were due to sustained higher 
normalized expression levels on OLA-free scaffolds throughout the three week period.  
Interestingly, the main effect of week showed an expression profile with a peak at week 
two, which was also seen with RhoA and OP expression levels. Overall, the key result 
for PPAR expression is that, like PPAR, expression levels were greatest on OLA-free 
scaffolds. 
  Unlike the  and  isoforms, the main effect of OLA did not have a significant effect on 
PPAR expression (p=0.56) (Figure 4.17).  Both the main effect of week and the 
interaction effect were significant, likely due to substantial up-regulations on all three 
scaffolds at week three.  Individual t-tests also showed no significant differences 




two and three 
both measured 






expressed due to 
OLA release.  
 In order to further analyze the effects of OLA on PPARs, ratios of expression levels 
were calculated for ANOVA.  First looking at /, the main effect of OLA shows that the 
presence of OLA leads to lesser expression of PPAR with respect to PPAR.  The 
expression ratios for cells on 1% and 5% OLA scaffolds were nearly identical.  Both 
main effects were significant, and the interaction effect was borderline significant (Figure 
4.18).   The interaction plot shows that the expression profiles for cells on all three 
scaffolds move similarly between weeks one and two.  Then, due to a dramatic increase 
in PPAR expression, the expression ratio drops on OLA-free scaffolds.  At week one, a 
t-test of expression ratios was significant between OLA-free and 1% OLA scaffolds, and 
only borderline significant (p=0.07) between OLA-free and 5% OLA scaffolds.  Similarly 
at week two, t-tests between both OLA scaffolds and OLA-free scaffolds were only 
borderline significant (p=0.09 for both).  Overall, the results show a very strong 
difference in the ratio of expression levels for PPAR and PPAR. 
 The expression ratio of / also showed highly significant changes due to OLA 
concentration, week, and the interaction of OLA by week (Figure 4.19).  The main effect 
 
Figure 4.17 - Expression levels of PPAR for each week.  Data 





Figure 4.18 – Expression ratio of the  and  isoforms of PPARs.  Star 
indicates statistically-significant difference (p<0.05) 
of OLA was a 
clear decrease in 
the ratio of / 
expression with 
increase in OLA 
concentration 
within the scaffold.  
This decreasing 
trend was very 
small between 
cells on OLA-free and 1% OLA scaffolds, and larger for 5% scaffolds.  As shown on the 
interaction plot, the expression ratio for cells on 5% OLA scaffolds increased by a very 
small margin each week.  At individual time points, the / ratio was significantly 
different between OLA-free and 5% OLA scaffolds at week one, and then between 5% 
OLA and the other two scaffolds at week three.   
 The expression ratio of / showed the greatest similarities between the three 
scaffolds (Figure 4.20).  The effect of OLA was not significant while the effect of week 
and the interaction effect of OLA by week were both significant.  The large changes in 
expression between weeks was apparent, and the interaction plot for the / ratio on 
each scaffold shows a peak at week two and then a decrease, which is likely due to 
PPAR up-regulation at week three for each scaffold.  Because the effect of OLA was 







Figure 4.19 – Expression ratio of the  and  isoforms of PPARs.  Star 
indicates statistically-significant difference (p<0.05) 
Polymer 
nanofibers have 









chondrocytes [240], and vascular endothelial [241].  In this study PCL scaffolds infused 
with oleic acid were fabricated to produce consistent nanofiber architecture.  
Characterization by SEM revealed insignificant differences (p=0.3) between the 
nanofiber architecture for 1% and 5% OLA scaffolds (OLA-free scaffolds were produced 
from 1% OLA scaffolds), with the mean fiber diameter values being within 20 nm of each 
other (Figure 4.1 (a-c)). The fiber diameter histogram for the two OLA concentrations 
shows only a slight shift in the scaffolds‘ fiber diameter characteristics (Figure 4.1 (d)).  
Large variations in fiber diameter are known to affect cellular functionality [139-141, 
193].  By verifying that the differences between the fiber diameters are nominal assures 
that the differences in cell responses observed in this study are not due to the 
differences scaffold architecture.  
Thermal analysis techniques were used to evaluate the differences in crystallinity 
and composition of different nanofiber scaffolds.  DSC was used to determine the % 





Figure 4.20 – Expression ratios for the  and  isoforms of PPAR 
important parameter that governs the degradation of semi-crystalline polymers such as 
PCL [111, 242, 243].  PCL degrades through hydrolysis of its ester bonds, and 
amorphous regions are more susceptible to hydrolysis than crystalline regions.  Thus, a 
scaffold with greater PCL crystallinity would likely degrade more slowly than a scaffold 
with substantially lower PCL crystallinity [237, 244].  As a caveat, enzymatic degradation 
of PCL does not preferentially target amorphous regions; enzymes may hydrolyze ester 









and 5% OLA 
scaffolds, and 
PCL pellets.  This would suggest that none of the scaffolds are more or less susceptible 
to degradation.  In the case of enzyme-free conditions, the mass loss data corroborates 
that hypothesis (Figure 4.3) by showing similarly low mass losses.  Clearly, enzymatic 
degradation was much more rapid than degradation mediated by water molecules 
diffusing through the polymer and hydrolyzing ester bonds.  With the large mass loss 
values in enzyme-assisted samples, bulk erosion certainly took place and that would 
permit more rapid OLA release.  However, both OLA scaffolds were only 1% and 5% 




electrospinning process as well as inclusion on OLA in the polymer had a negligible 
effect on its crystallinity.  Further, the similarity in the % crystallinity, and the similarity in 
mass loss values accounting for enzyme activity suggest that OLA itself does not 
increase degradation.   
TGA is a useful technique to evaluate the composition of materials.  For the 5%, 1%, 
and OLA-free scaffolds, they were expected to contain 95%, 99%, and 100% PCL 
respectively.    Although the mass loss during TGA for 5% scaffolds was slightly greater 
than the expected value 95% (Figure 4.2 (b)), it was still significantly different than OLA-
free, 1% OLA, and untreated PCL.  This may be due in part to the encapsulation 
efficiency for OLA being less than 100%, and that will be examined in the future.  Weight 
loss within the chosen temperature range is associated primarily with loss of PCL [242], 
although some OLA is also likely to oxidize or degrade away [245].  Most importantly, 
this data confirms that the 5% OLA scaffolds lost less mass than the 1% OLA and OLA-
free scaffolds.  This difference is attributed due to higher amount of OLA present in the 
scaffold.  
In order for a synthetic tissue scaffold to augment the natural healing process of the 
bone, it must support adhesion and proliferation of MSCs. For MSCs, trafficking and 
migration to an injury site occurs in a very carefully coordinated manner that is not yet 
fully understood [147, 148, 246].  Once at the site, the cell-cell and cell-ECM interactions 
significantly influence the capacity of the progenitor cells to differentiate into matrix-
producing cell phenotypes [184, 185, 247].  Thus the initial adhesion and proliferation of 
MSCs is a key requirement for the success of a tissue engineered scaffold for bone 
regeneration. 
In this study, MSCs were cultured on nanofiber scaffolds for up to 7 days in 




allowed to adhere and proliferate on the scaffold surfaces. Cell viability on nanofiber 
scaffolds was measured using MTT assay during the log phase growth (i.e. after 1 and 4 
days of culture).  This assay measures metabolic levels by detecting the activity of 
mitochondrial dehydrogenases, though it cannot indicate the task for which cells are 
expending energy (i.e. cell division, migration, etc.).  Our results show that even though 
the OLA-free scaffolds support highest metabolic activity of MSCs, all scaffolds are 
clearly capable of supporting viable MSC cultures (Figure 4.4).  Further, the live cell 
stain and cell coverage measurements show very strong evidence that the cells are 
adhering to all the scaffolds. However, there are clear differences in the cell coverage on 
the scaffolds with different OLA concentrations.  These results show that the cell 
coverage on the scaffolds decreases as the OLA concentration increases.  This could be 
due to individual cells spreading to a lower degree and/or fewer cells populating the 
scaffolds.  For 5% OLA scaffolds, individual cells appear to be less spread than those on 
1% OLA and OLA-free scaffolds, and this difference is especially apparent at day 7 
(Figure 4.5).    Further, individual cells on 1% OLA scaffolds displayed a similar 
spreading morphology as those on OLA-free scaffolds, but the cell density is visibly 
lower than that on OLA-free scaffolds.  Given that fiber diameters for the three scaffolds 
are very similar, the differences in cell behavior (spreading and colonization) can 
attributed to the OLA released from within the nanofibers (Figure 4.6).  The general 
trend of decreasing metabolic activity with increasing OLA concentration matches well 
with MTT results.  Overall, it appears that the significant differences in cell populations 
due to OLA are result from a combination of decreased proliferation as well as a lesser 
degree of cell spreading. 
Polymer nanofiber scaffolds offer significant benefits for bone tissue engineering due 




molecules within the polymer [248].  The key design feature investigated in this work 
was the inclusion of oleic acid (OLA), a fatty acid that has been linked to increased 
phenotypic behaviors by osteoblast cell.  Fatty acids are a class of biomolecules that 
have not yet been extensively investigated as a means to enhance mineralization on 
synthetic scaffolds.  The most likely mechanism of action of OLA on osteoblasts is 
through activation of peroxisome proliferation activator receptors (PPARs) [230, 249].  
The activation of the gamma isoform, PPARγ is sufficient to differentiate capable cells 
into the adipocyte phenotype [250], but the osteogenic influences of PPARs are still 
unclear.  OLA has a low affinity for PPAR and -, and the greatest affinity for 
PPAR[177], an isoform with a very broad range of functions and has been implicated 
in mineralization by osteoblast precursor cells [143]. 
In order to evaluate the effect of OLA on osteogenic differentiation of MSCs, the 
expression of several key phenotypic markers were investigated.  Mineralization was 
evaluated by measuring ALP activity and calcium deposition on scaffold surface.  ALP is 
a key component of bone matrix vesicles; it cleaves organic phosphate esters, thus 
potentiating Ca-P crystal nucleation [149, 205, 251].  Pre-osteoblasts typically up-
regulate ALP as they differentiate into osteoblasts, and then maturing osteoblasts down-
regulate ALP before they either undergo apoptosis or become terminally differentiated 
osteocytes [39].  As such, it is expected that the statistical significance for the interaction 
of treatment by time would be highly significant.  ALP activity after 1 week of 
differentiation on all the scaffolds was much lower than that after 2 and 3 weeks of 
differentiation (Figure 4.7). However, the cells on 5% OLA scaffolds exhibited higher 
levels of ALP activity for the entire duration of culture in osteogenic media, followed by 




enhanced bone matrix vesicle synthesis by cells on 5% OLA scaffolds as compared to 
that on other scaffolds. 
The ALP expression by pre-osteoblasts and mature osteoblasts leads to deposition 
of bone mineral matrix on the scaffolds.  The mineralization was characterized by 
measuring the amount of calcium deposited on the scaffold surfaces (Figure 4.8).  Our 
results suggest that 5% OLA scaffolds supported highest mineralization. Further, there 
were insignificant differences in calcium deposition on all the scaffolds for up to 2 weeks 
of differentiation.  This may be due to lower levels of ALP activity.  However, there was 
significant increase in calcium deposited on the scaffolds after 3 weeks of differentiation.  
Higher levels of ALP activity after 3 weeks of differentiation on 5% OLA scaffolds 
suggests that the cells on 5% OLA scaffolds would continue deposition of bone mineral 
matrix at a higher rate than that on other scaffolds.  
SEM and EDX can provide valuable information regarding cell colonization and 
mineralization patterns.  By detecting the presence of overlapped Ca and P on the 
scaffold surface, EDX can make semi-quantitative measurements of surface mineral 
deposits and demonstrate that they are phases of Ca-P.  Spatial elemental mapping with 
EDX was also used in imaging mode to detect the distribution of Ca and P deposition on 
scaffold surfaces.  EDX elemental map shows large Ca-P aggregates on the scaffold 
surfaces.  In many cases cells were in intimate contact with these aggregates, and non-
cellular fibrils (potentially collagen) were clearly visible (Figure 4.9 (A)).  High 
magnification EDX elemental maps also confirmed the presence of small Ca-P 
spherulites that had adsorbed to the nanofiber architecture.  In fact, combined SEM/EDX 
images at high magnification show these spherulites beneath the top-most nanofiber 
layer (Figures 4.10 (A, D) red phase).  It should be noted that for all scaffolds, the EDX 




Ca and P with an approximate peak ratio of 1.6 to 1.7 (Ca:P) (Figures 4.10 (C, F)), and 
naturally occurring hydroxyapatite has a Ca:P ratio of 1.66.  Precise stoichiometric 
analysis is difficult with EDX since the scaffolds are coated with gold, and the proximity 
of the gold and phosphorus peaks in the scans make it difficult to de-convolute the 
individual signals.   
OP and OC are two bone matrix proteins that are differentially regulated by 
osteoblasts during de novo bone matrix production. OP is an acidic phosphoprotein that 
contains a highly-conserved aspartic acid-rich domain believed to facilitate calcium 
binding, and it also contains a separate domain capable of binding to integrins [41, 42, 
154].  OC contains a calcium-binding glutamic acid sequence, and although it was 
originally believed to be involved with hydroxyapatite nucleation, it is now believed to be 
more closely associated with bone tissue remodeling [252].  Both proteins play important 
roles in bone tissue maintenance, and they contain multiple phosphorylation and 
sulfation sites that may expose or hide cell-binding domains associated with increased 
or decreased matrix production, thus their expression by cells is critical for long term 
success of bone scaffolds.  Immunofluorescence images showed cells on all scaffolds 
had secreted both OC and OP (Figure 4.13).  OC was deposited on surfaces without 
discernable differences between scaffolds, whereas OP appeared in greater abundance 
on 5% OLA scaffolds.  This observation was supported by qPCR data which suggested 
an overall increase in OP expression on 5% OLA scaffolds.  The cumulative measure is 
appropriate because as cells express the OP gene, it will be translated, packaged, and 
then secreted into the extracellular environment where it can accumulate. 
 The role of PPAR in MSC fate processes is becoming clear, and it is regarded as a 
master regulator for adipocytic differentiation from progenitor cells [145, 253].  However, 




some preliminary evidence that PPAR/ agonists enhance bone formation under 
certain conditions [143, 191].  This work elucidated the differential activation of each of 
the three PPARs by measuring their respective gene expression levels using qPCR.  
Quantitatively measuring PPAR gene expression is an accurate assessment of 
activation because PPAR expression has been inversely related to dose exposure of 
PPAR agonists to specific isoforms [254].  In other words, as any one PPAR type (, , 
or ) is activated by an agonist, its expression may be down-regulated. 
 The results showed the greatest PPAR expression by cells on OLA-free scaffolds, 
followed by 1% and then 5% OLA scaffolds (Figure 4.15).  This indicates that, due to 
OLA release from 1% and 5% scaffolds, PPAR is being activated at the greatest levels 
on 5% OLA scaffolds.  OLA-free scaffolds also supported the greatest expression of 
PPAR, followed by 5% and then 1% scaffolds.  The finding that OLA had no significant 
effect on PPAR expression was predictable because OLA has and 8-fold lower affinity 
for PPARthan for PPAR   Further, OLA is noted to nominally activate PPAR and 
efficiently activate PPAR [177, 255].  It is important to note that for both PPAR and 
PPAR, the differences in expression levels on 1% and 5% scaffolds was very small 
(Figures 4.15 and 4.16).  Yet our previous work showed very large differences in 
mineralization and ALP activity.  To account for this difference, the expression ratios 
between each of the three PPARs were examined.   
 Keeping in mind that OLA has an 8-fold greater affinity for PPAR than PPAR, and 
that PPAR is viewed as a master regulator of adipocytic differentiation [231], the 
expression ratio for / is an important measurement to explain OLA-induced changes in 
osteoblast behaviors.  The overall effect of OLA showed both 1% and 5% scaffolds 
supporting nearly identical expression ratios (Figure 4.18), and both were lower than 




released from nanofibers is binding to and activating PPAR at significantly greater 
levels than PPAR.  A similarly-important observation can be made about the ratio of / 
expression (Figure 4.19), in which the overall effect of OLA led to decreases in 
expression of PPAR to PPAR  In this case, there were notable differences between 
levels on 1% and 5% OLA scaffolds as well as OLA-free scaffolds.  Taken together, this 
may explain for why osteoblast behaviors in this study and our previous one were 
expressed in greater amounts on 5% OLA than on 1% OLA scaffolds.   
 A recent study examining nuclear receptor expressions in adipogenic and osteogenic 
conditions demonstrated that in osteogenic conditions (ie. differentiation by 
glucocorticoids), PPAR and  were expressed at nearly equal levels during 
differentiation in the absence of PPAR agonists [231].  This study, and others examining 
PPARs and bone also did not examine PPAR [256], although it is clear here that 
PPAR is differentially-expressed.    With this in mind, the PPAR expression results here 
best explain observed differences in osteoblast behaviors when presented as relative 
ratios of expression.  Clearly, OLA released from the PCL nanofibers has altered the 
expression ratios and increased osteoblast behaviors significantly on 5% OLA scaffolds. 
There is one significant concern for a confounding factor influencing the enhanced 
osteogenic behaviors by cells on 5% OLA scaffolds.  Cell coverage measurements 
(Figure 4.6) and calcein images (Figure 4.5) showed that by day 7, cells on 5% OLA 
scaffolds remained very small, with lower cell coverage and observably smaller size.  In 
order to achieve the cuboidal morphology associated with osteoblasts, differentiating 
progenitor cells may need to remodel their cytoskeletons to a greater degree or more 
rapidly.  RhoA is a Rho-GTPase associated with remodeling of actin filaments, and its 
expression is necessary for progenitor cells to differentiate into osteoblasts [184, 185].  




OLA-dependent manner, we ruled out over-expressed RhoA as a possible confounding 
factor. 
In summary, the results present a clear conclusion about the efficacy of infusing OLA 
into PCL nanofibers for enhancing bone regeneration.  The combined SEM/EDX images 
(Figures 4.6 and 4.7) show extensive mineral deposition on all the scaffolds, particularly 
on 5% OLA scaffolds.  This judgment is strongly supported by the results from the Ca 
and ALP assays which both indicate that mineralization is greatest on 5% OLA scaffolds.  
Furthermore, von Kossa stains, which stain phosphates, show a dense heterogeneous 
stain distribution that is associate with bone nodule formation [207].  Finally, densely-
deposited non-collagenous bone matrix proteins, notably OP on 5% OLA scaffolds, 
shows that the mineralization is progressing from small Ca-P spherulite deposits into 
larger bone nodules.  All of these strongly data indicate that 5% OLA supports the 
greatest de novo tissue synthesis. 
 
4.6 Conclusions 
This work represents a novel approach of enhancing bone formation on synthetic 
scaffolds by taking advantage of the simplicity of incorporating stable lipids into polymer 
nanofibers.  This was the first attempt to demonstrate that lipids could differentially affect 
primary cells in serum-containing media.  The fabrication results clearly demonstrated 
that any differences in cellular response would not derive from the insignificant 
architectural differences.  Cells began to respond to scaffolds with different OLA 
concentrations beginning on the first day after seeding, as shown with different cell 
coverage and metabolic activity.  After seven days, cells were differentiated by 
glucocorticoids and the differential response continued through 3 weeks of culture, with 




mineralization.  Further, this work demonstrated that two PPAR isoforms –  and  – 
were expressed at significantly different levels, and at different ratios with respect to 
each other and PPAR.  This expression is a suitable surrogate measurement for 
activation, and thus the likely mechanism of action for increasing osteoblast activities 
was via PPAR signaling. 
 
4.7 Future work 
  The most important piece of information to gather in the future will be release 
data for OLA.  Prior to this portion of work being publishable, the release profile must be 
measured through 28 days – the length of time that cells were cultured on these 
scaffolds.  One attempt was already made for quantifying OLA release with gel 
chromatography/mass spectroscopy (GC/MS), however the results were partially 
unusable were excluded from this chapter.  However, this is a key piece of data and a 
second release study will be performed using GC/MS to measure the release at days 1, 
4, 7, 14, 21, and 28.  Additionally, the encapsulation efficiency of OLA will be measured 
using GC/MS in order to accurately determine the initial quantities of OLA incorporated 
into the PCL nanofibers.   
 The osteoblast behaviors measured in this chapter demonstrated that OLA was 
effective in enhancing several markers of bone matrix deposition, and that the OLA was 
likely acting through PPARs.  The next step in demonstrating the effectiveness of these 
PCL-OLA scaffolds is to evaluate their biocompatibility osteoconductivity in vivo.  
Traditionally, this has been done with post-mortem histological analysis of implanted 
scaffolds.  However, new imaging technologies developed over the last decade include 
the ability to probe for specific proteins and gene transcripts without sacrificing animals, 




This, along with post-mortem histological analysis, is an approach which would permit 
similar gene expression measurements as well as histomorphological evaluation of 
osteogenesis on PCL-OLA scaffolds. 
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5.1 Chapter summary 
 This chapter builds on chapters 3 and 4 by investigating the effects of OLA and HAp 
on biocompatibility and osteogenesis in vivo.  The experimental design tested four 
scaffolds – HAp-free, OLA-free; 3% OLA; 10% HAp; and 3% OLA, 10% HAp.  This 
allowed for the evaluation of each design factor separately and together.   For 
biocompatibility, scaffolds were implanted in paravertebral muscles and then harvested 
after one or four weeks.  They were then stained with hemotoxylin and eosin (H&E) and 
evaluated for changes in cellular elements and cellular features.   For osteogenesis, 
scaffolds were implanted in calvarial defects and harvested after four weeks.  The 
scaffolds and the adjacent tissue were stained with toluidine blue or hemotoxylin and 
assayed for tartrate-resistant acidic phosphatase (TRAP) activity.  The results showed 
that all scaffold elicited moderate to severe immune response after one week, and by 
week four that response had reduced significantly.  Bone morphometric analysis showed 
that both HAp and OLA individually caused enhanced osteoid production in the adjacent 
bone tissue, and more pre-osteoblasts, osteoblasts, and osteoclasts had populated 
those scaffold surfaces than control scaffolds (HAp-free, OLA-free).  Scaffolds with both 
HAp and OLA showed the most osteoid in adjacent bone, the most pre-osteoblasts, 
osteoblasts, and osteoclasts, and then most bone deposition on the implant.   Thus 
although both design factors individually enhance osteogenesis, combining the two 
design factors together appears to have positive synergy. 
 
5.2 Motivation and Aims  
 Bone tissue replacements have traditionally been derived from two sources – 
autograft and allograft.  Autografted bone offers a non-immunogenic, biologically-active 
construct at the expense of tissue at a donor site, and thus availability and donor site 




autografted bone, but immunogenicity and sterility are major concerns, and sterilization 
procedures such as irradiation or freeze-drying may alter mechanical and biochemical 
integrity [7, 8].  Synthetic tissue scaffolds offer an attractive option for both availability 
and sterility, but these are still considered an inferior clinical choice to allograft and 
autograft because of inferior integration and necrosis related to stress shielding [4, 6, 9].  
Thus, synthetic tissue scaffold design strategies over the last decade and more have 
aimed at making substantial progress in mimicking various features of natural tissue in 
order to enhance osseointegration [10, 11].   
 Previous investigations in chapters 3 and 4 have shown that simple modifications to 
poly(-caprolactone) (PCL) nanofiber scaffolds can significantly alter the expression of 
key osteoblast genes and behaviors.  Oleic acid (OLA) is an -9 monounsaturated fatty 
acid that is an agonist for peroxisome proliferator-activator receptors [255], a class of 
nuclear membrane receptors for which fatty acids are ligands [177].  OLA has been 
shown to increase key osteoblast behaviors such as alkaline phosphatase (ALP) activity 
in vitro and we have shown evidence of concurrent PPAR activation with ALP up-
regulation due to OLA release from nanofiber scaffolds.   
 Concurrently, including OLA in electrospinning solutions allows for an additional 
osteogenic design factor – hydroxyapatite (HAp) nanoparticles.  OLA acts as a 
surfactant between the hydrophobic PCL and hydrophilic HAp, thus preventing HAp 
particle agglomeration and maintaining the scaffold‘s fibrous morphology.  HAp is the 
major inorganic component of natural bone tissue, and the inclusion of HAp 
nanoparticles into nanofibrous scaffolds has been shown by our lab and others to 
moderately increase markers of osteogenesis in vitro [32, 175].  However, both design 




scaffolds evaluated in vitro rely on glucocorticoid-induced osteoblastogenesis which is 
different from in vivo differentiation which occurs by a multitude of soluble signals. 
 In this chapter, we evaluated the effects of OLA and HAp on in vivo biocompatibility 
and osteogenesis.  For biocompatibility, scaffolds were implanted in rat paravertebral 
muscles and harvested at days 7 and 28, and then they were examined for changes in 
cellular and tissue characteristics with a hematoxylin and eosin (H&E) stain.  For 
osteogenesis, scaffolds were implanted in critically-sized rat calvarial defects and 
harvested at day 28.  Implant and mineralized tissue analysis were performed using 
histomorphometric techniques for osteoblasts and osteoclasts. 
 
5.3 Methods 
5.3.1 Fabrication and characterization of nanofibrous scaffolds 
 Scaffold fabrication was performed with electrospinning, which has been previously 
described.  Briefly, poly(-caprolactone) (PCL) was dissolved in chloroform at 12% w/w, 
oleic acid sodium salt was dissolved in methanol at 3% of the weight of PCL, and the 
two solutions were mixed with a chloroform:methanol ratio of 3:1.  For hydroxyapatite 
(HAp) scaffolds, HAp was mixed into the electrospinning solution at 10% of the solid 
weight.  The solution was electrospun with a blunt-tip 18-gauge catheter at a tip-to-
collector distance of 3-3.5‖, applied voltage of 18-21 kV, and volumetric feed rate of 2.2-
2.8 mL/hr, depending on the solution.  OLA-free scaffolds were obtained for both Hap-
free and 10% HAp scaffolds by soaking the scaffolds in methanol for 24 hours.  Scaffold 
morphology and composition was verified as previously described. 
 




 Surgeries were performed by a board-certified veterinary surgeon in sterile 
conditions according to ASTM standard F-763-04 for short-term screening of biomedical 
implants.  12 male Wistar rats were used for the biocompatibility study in accordance 
with guidelines developed by NIH Institutional Animal Care and User Committee 
(IACUC).  6 mm discs of each scaffold were cut with a sterile biopsy punch prior to 
surgeries, and then sterilized by UV exposure for 30 min and successive washing with 
deionized water and PBS with an additional 10 min UV exposure between and after the 
washes.  All animals received an analgesic injection of Buprenorphine (0.1ml, 0.005mg) 
preoperatively and 6 and 24 hours postoperatively.  Incision sites and surrounding areas 
were shaved and disinfected with povidine iodine. 2-3 cm dorsal midline skin incisions 
were made in the lumbar spine region.  For implantation, skin was retracted laterally and 
four muscle pouches (two cranial and two caudal) were made in the paravertebral 
muscle on the left and right sides of the spine.  The muscle pouch was closed with a 
single cruciate pattern suture of 5/0 nylon, and the skin then closed with surgical staples.  
One rat (#3) died approximately 20 hours after surgery, and another rat (#6) exhibited 
distress for the first 24 hours after surgery but then recovered.  All others recovered from 
surgeries without concern.  After 7 and 28 days, 6 of the 12 animals were sacrificed and 
euthanized with CO2.  Immediately after euthanasia, the implant as well as 1-6 mm of 
surrounding tissue was removed from the implantation site using a 10 mm biopsy punch 
and placed in formalin.   
 For histological analysis, samples were dehydrated in ethanol and embedded in 
paraffin.  Sections were taken from the middle of the implant and stained with 
hematoxylin and eosin (H&E).  A board-certified veterinary histologist then examined the 
sections for cell and tissue elements.  Guidelines described by ATSM standard 981 were 




cells, macrophages), cellular changes (giant cells, necrosis, fibrosis), and tissue 
changes (fat infiltration, foreign material, granuloma).   
 
5.3.3 In vivo osteogenesis and bone histomorphometry 
 Osteogenesis was examined in rat calvarial defects created in the same rats used for 
biocompatibility studies.  Scaffold sterilization and animal handling procedures were the 
same as in the biocompatibility study.  For the surgeries, incision sites were shaved, and 
a dorsal midline incision was made and the skin was retracted laterally.  A 6 mm biopsy 
punch was used to create calvarial defects in the left and right sides of the rats‘ skulls 
and the defect site was rinsed extensively with saline.  Sterile 6 mm scaffolds were 
placed in the defects and the skin was closed over them using 5/0 nylon sutures.  When 
animals were sacrificed for biocompatibility studies as described above, the skulls were 
harvested and fixed in formalin.   
 For histological analysis, specimens were kept un-decalcified prior to dehydration.  
Successive incubation at 4oC in ethanol (70% up to 100%) dehydrated the tissue 
samples and then they were infiltrated twice for 24 hours (48 hours total) at 4oC in 100 
ml destabilized methylmethacrylate (MMA), 14 ml nonylphenyl-polyethyleneglycol 
acetate (NPG) and 0.33 g anhydrous benzoyl peroxide (BPO) prior to MMA 
polymerization.  Polymerization was initiated at 4oC in 100 ml MMA, 14 ml NPG, 0.55 g 
BPO and 500 ml N,N dimethyl-p-toluidine 99%.  Sectioning was performed on a 
motorized Leica RM2165 microtome using tungsten-carbide blades.  Sections were 
selected to pass through the middle of implanted nanofiber scaffolds and the histologist 
ensured that all specimens had the same orientation.   For osteoblast analysis, sections 
were stained with toluidine blue and analyzed at 20x magnification.  Osteoclast analysis 





Table 5.1 – Scoring criteria for cellular changes 
and cellular elements in H&E stained slides 
Osteoclast slides were stained with faded hematoxylin for visualization of multinucleated 
bodies.  Each image was subjected to a background subtraction so that the background 
appeared white for clearer viewing  
 
5.3.4 Statistical analysis 
 For biocompatibility values, a Mann-Whitney non-parametric test was used to 
calculate the effect of week, HAp, and OLA on measurements.  Significance was defined 
at the 95% confidence level.  Some treatments had a uniform response and all samples 
contained identical scores, which were incompatible with the Mann-Whitney test.  One 
sample score value was then changed by 0.02 to allow analysis to proceed.  
Significantly different groups were denoted by the symbol ‗*‗. The sample size for bone 




5.4.1 In vivo Biocompatibility 
 In order to assess the differences in the biocompatibility and inflammatory response 
to osteogenic design factors, scaffolds were implanted into paravertebral muscle spaces 
according to ASTM standard F-763-04.  After 7 or 28 days, the implants were removed 
and examined histologically for changes in cellular elements and changes (Table 5.1).  
To control for architecture, scaffolds 
without HAp and leached of OLA were 
used as negative controls (12-3 
leached), and test scaffolds were used 





Figure 5.1 – Scores for biocompatibility evaluation for 
implants, either 1 or 4 weeks post-implantation.  
Statistically significant (p<0.05) point in week 1 is 
denoted by ‘*’.  PMN refers to polymorphonuclear 
HAp (12-3-10 leached) and 
OLA (12-3) respectively.  
Scaffolds with both HAp and 
OLA were used to evaluate 
any synergistic effects of the 
two design factors (12-3-10).  
All implant sites were 
characterized by localized 
destruction of the muscle 
fibers and the formation of 
fluid-filled spaces immediately 
adjacent to the scaffolds.  
There were no discernable 
morphological differences in 
tissue response due to 
scaffold features (ie. HAp 
and/or OLA).   
 After seven days, 
contained large numbers of polymorphonuclear leukocytes (PNMLs), which were 
identified as primarily eosinophils with a small number of neutrophils also present 
(Figure 5.1).  These PMNL were dramatically fewer after 28 days, and plasma cells, 
which were nearly absent after 7 days, had begun to populate the space near the 
implant surfaces.  Additionally, both necrosis and fibrosis, which were minimal to mild 





Figure 5.2 – H&E stained implants and the surrounding tissue either 1 or 4 weeks post 
implantation 
difference for all parameters and time-points, and that was the necrosis between 12-3 
Leached (OLA-free) and 12-3-10 (10% HAp, OLA-free) scaffolds.   
 Visually, all the nanofibrous scaffolds appear to permit cellular infiltration.  The 
greatest cellular infiltration at week one occurred on scaffolds with both HAp and OLA 
(12-3-10) (Figure 5.2), which also had a high score – four – of PMNL cells.  These 
PMNLs were identified primarily as eosinophils (brick red cells in all H&E images) with 
some neutrophils, both of which are immune cells with high mobility and relatively small 
size (12-17 m) [257, 258].  Cellular infiltration seems to be less at week four than at 
week one, as is the score for PMNLs, which also suggests that PMNLs are highly active 
in infiltrating scaffolds.  At week four, cells have still infiltrated scaffolds, and thus some 
of the other cell phenotypes will also infiltrate the scaffolds. 
 Finally, tissue necrosis scored between mild and moderate for all scaffolds, with the 
highest score on HAp-free, OLA-free (12-3 leached) scaffolds.  Fibrosis was relatively 
consistent across all scaffolds, with only a minimal presence.  By week four, necrosis 
had decreased to a minimal level and fibrosis was nearly absent.  The changes in 






Figure 5.3 – Osteoblasts and implants, 4 weeks post-implantation 
5.4.2 In vivo osteogenesis and bone histomorphometry  
In order to evaluate the osteoconductive action of the two design factors, nanofibrous 
scaffolds that had been implanted in rat calvarial defects for four weeks were examined 
histomorphologically for osteoblasts, osteoclasts, and bone or osteoid deposition.  
Osteoblasts were stained with toluidine blue (Figure 5.3), and osteoclasts were stained 
with hemotoxylin (Figure 5.4) and also assayed for TRAP.  Staining results were used to 
analyze the cells and tissue in and around the nanofiber scaffolds.  An analysis of the 
mineralized tissue adjacent to the implants demonstrated several notable differences 
between scaffolds.  First, the percent of bone surface with osteoid (OS/BS %, Figure 
5.5) was lowest on HAp-
free, OLA-free (12-3 
leached) scaffolds, then 
greater on either 10% 
HAp (12-3-10 leached) 
or 3% OLA (12-3) 
scaffolds, and greatest 
on scaffolds with both 
10% HAp and 3% OLA (12-3-10).  The same trend was described for two osteoblast 
measures: the number of osteoblasts lining the bone surface (Ob.S/BS), and the percent 
of osteoid with osteoblasts adjacent to bone surface (OS(Ob+)/BS).  In contrast, the 
reverse trend was observed for the percent of quiescent surface (QS/BS, or surface with 
no osteoblast or osteoclast related activity), and for the number of osteoblasts per 
osteoid surface (N.Ob/OS).  Overall, these results indicate that scaffolds with both 
osteogenic design factors support the greatest neo-mineralization and osteoblast activity 





Figure 5.4 – Osteoclasts and implants, 4 weeks post-implantation 
 
Figure 5.5 – Mineralized tissue measurements of implants, 4 
weeks post-implantation 
 Analysis of the 
implants was 
performed using the 
same stains.  The 
histologist noted that 
cellular infiltration 
was minimal, but all 
implant surfaces 
were heavily 
covered by cells, and this trend can be seen on any of the stained slides (Figures 5.3 
and 5.4).  Osteoblast, pre-osteoblasts, and osteoclasts were identified with the stains, 
and all showed the lowest population presence on scaffolds with neither OLA nor HAp 
(12-3), and the most on scaffolds with both factors, and a milieu on scaffolds with either 
HAp or OLA (Figure 5.6).  The percent of bone tissue in the tissue surrounding the 
implant (BV/TV%) and the bone surface density (BS/TV) showed similar trends (Figure 
5.7), which were slightly different from the analysis of cells adjacent to the implanted 
scaffolds.  In both cases, 
scaffolds with HAp (12-3-
10 leached and 12-3-10) 
supported the highest 
levels of osteoid by both 
measurements.  Overall, 
osteoblasts, pre-
osteoblasts, and 





Figure 5.6 – Measurements of the cell types lining the implants 
 
Figure 5.7 – Analysis of tissue 
deposited directly onto scaffolds 
the osteogenic 
design factors, and 
the two design 
factors together 
resulted in the 
greatest presence of 
important bone 
remodeling cells on the implant surfaces.  Based on the amount of osteoid deposited in 
the tissue adjacent to the implants, HAp induces a greater osteogenic response than 
OLA.   
 
5.5 Discussion 
 In order to evaluate the biocompatibility and osteoconduction of nanofiber scaffolds 
with and without HAp and OLA, the scaffolds were implanted either in paravertebral 
muscle pouches or calvarial defects.  Nanofiber constructs offer an attractive platform for 
implants for several reasons.  As has been demonstrated here, nanofiber scaffolds may 
carry multiple design factors within the same construct.  Additional modifications to these 
scaffolds, for example growth factor or peptide delivery, may yet be incorporated.  
Furthermore, the nanofibrous morphology 
allows water and enzymes a high level of 
access to the polymer so that it may degrade 
at a fast enough rate so as to permit osteoid 
deposition and neo-vascularization throughout 
the full scaffold volume.   




points regarding the two design factors of interest.  First, neither design factor 
significantly increased the inflammatory response relative to HAp-free, OLA-free 
scaffolds (Figure 5.1).  Second, in an osseous environment, the design factors 
individually and synergistically enhance new osteoid deposition (Figure 5.5) and pre-
osteoblast, osteoblast, and osteoclast populations (Figure 5.6).  These two observations 
are tied together because normal fracture healing involves an inflammatory response, 
during which immune cells such as granulocytes and macrophages are recruited to the 
wound to remove microbes and debris before osteoblasts and chondroblasts arrive to 
begin tissue remodeling [259].  The nearly minimal and absent necrosis and fibrosis, 
respectively (Figure 5.1), at week four is permissive for the tissue remodeling that was 
observed in calvarial defects after four weeks.   
 Pre-osteoblasts and osteoblasts have a dissimilar morphology and gene expression 
profile, with osteoblasts expressing mineralization-associated genes such as alkaline 
phosphatase and pre-osteoblasts expressing proliferation-related genes [39, 206].  With 
both osteoblasts and pre-osteoblasts present on scaffolds that have been implanted for 
four weeks, it is likely that these cells have been recruited from the general cell 
population.  Cell recruitment is a key difference between in vivo and in vitro culture 
conditions because in vitro culture conditions typically involve only a single cell-seeding 
event and differentiation by dexamethasone, a glucocorticoid, rather than soluble growth 
factors [260].  As a result of those two conditions, it is difficult to conceive of a series of 
in vitro events which would permit these two distinct phenotypes to co-exist in large 
numbers.  Further, the balance of matrix deposition by osteoblasts and matrix resorption 
by osteoclasts dictates the net rate of osteoid and bone formation.  However, if there are 
active osteoclasts within the cell population, dexamethasone down-regulates 




vitro [261, 262].  These differences are important to keep in mind when comparing the 
results presented herein with results from in vitro cell experiments.   
 With regards to the two osteogenic design factors, OLA and HAp, there is clear 
evidence that neither factor substantially increases the inflammatory response or 
decreases the biocompatibility of the nanofibrous construct (Figure 5.1).  Scaffolds with 
HAp nanoparticles also showed the greatest overall support for osteoid formation and 
bone tissue remodeling, based on the numbers of pre-osteoblast, osteoblast, and 
osteoclasts (Figure 5.5 and 5.6), and the analysis of tissue surrounding the implant 
(Figure 5.6 and 5.7).  Although OLA increased the numbers of bone-related cells and 
new osteoid (Figure 5.5 and 5.6), the effect of OLA on bone deposition onto the 
scaffolds was less clear.  OLA slightly increased the percent of bone tissue for HAp 
scaffolds, but the opposite effect was observed on HAp-free scaffolds (Figure 5.7).  
Taken together this indicates that HAp has a more osteoconductive effect, and that OLA 
may be synergistically osteogenic in the presence of mineralized scaffolds.    
 
5.6 Conclusions  
 Scaffolds were fabricated to evaluate the effects of HAp nanoparticles and OLA on 
biocompatibility and bone formation in vivo.  The results indicated that neither design 
factor negatively affected biocompatibility separately or in combination.  All scaffolds 
caused mild to moderate necrosis and the recruitment of PMNLs to the implant site after 
one week, and both these inflammatory markers were minimal or absent by four weeks.  
A histomorphological analysis of the cells and tissue on and adjacent to the implants 
revealed that both factors increase the numbers of bone-related cells.  Both factors also 
increased the new osteoid on mineralized tissue, but only HAp increased the bone 





5.7 Future work 
 This work on its own shows that both OLA and HAp enhance new osteoid 
production, with HAp being the more osteogenic of the two design factors.  This work 
combined with chapter 3 which shows only modest gains in ALP due to HAp in vivo and 
decreases in type I collagen expression.  The disparity between the in vivo and in vitro 
osteogenesis results is an area of research that should be explored. One likely cause for 
the differences is the differentiation method.  In vitro osteoblastogenesis is achieved by 
glucocorticoid treatments, while in vivo differentiation is achieved by soluble signals such 
as bone morphogenic proteins, fibroblast growth factors, WNTs, and hedgehog proteins 
[263].  Medical imaging technologies such as transcription MRI have been developed to 
the point of being able to quantify active gene transcription in vivo [264, 265].  Changes 
in osteoblastogenesis markers such as Runx2/Cbfa1, osterix, ALP, Col1, and 
osteoprotegerin due to HAp in nanofibers should be investigated.  For long-term work, 
osteo-immuno crosstalk is highly complex [44, 45] and likely to change due to these 
osteogenic design factors.  An accurate profile of just a few differential responses in vivo 
would provide valuable insight which can be used to incorporate additional osteogenic 
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6.1 Chapter Summary 
The goal of this chapter was to develop a biodegradable, antimicrobial tissue scaffold 
that could deliver various antibiotics while providing architecture for tissue regeneration.  
This study determined the release profile and bactericidal efficacy of rifampicin (RIF) 
against Gram-positive and Gram-negative bacteria in static-flow conditions.  Antibiotic-
loaded scaffolds were fabricated by electrospinning poly (-caprolactone) (PCL) with RIF 
so that the mass of RIF was either 9% or 16% of the final solid mass.  SEM was used to 
quantify scaffold morphology based on the fiber diameters measured, and scaffold 
composition was verified using thermogravimetric analysis (TGA).  The release of RIF 
from scaffolds was measured at hours 1, 4, 8, and 24 by colorimetric assay.  In order to 
determine the bactericidal efficacy, RIF scaffolds and RIF-free scaffolds were placed in 
either lysogeny or trypticase soy broth and inoculated with either Pseudomonas 
aeruginosa (PA) or Staphylococcus epidermidis (SE), respectively.  Each hour for 0-6 
hours, aliquots of the medium were removed and filtered through a membrane for 
counting with fluorescent microscopy.  Bacterial growth and extracellular polysaccharide 
secretion was also examined using SEM on scaffolds after 6 hours of bacterial growth.  
Results showed that mean fiber diameters were within 200 nm for all three scaffolds, 
with 9% RIF scaffolds being significantly different than the other two.  TGA confirmed 
that the 9% and 16% RIF scaffolds contained the intended amounts of RIF, and the 
release profiles for both RIF scaffolds showed significant differences in the mass 
released.  Both profiles exhibited a burst during the first 8 hours, and by 24 hours both 
scaffolds had stopped releasing RIF.  The cumulative release profile for 16% RIF was 
greater at each time point, and the duration of release was longer than that of 9% RIF 
scaffolds.  Bacterial growth on RIF-loaded scaffolds was hindered compared to control 




and PCL-RIF scaffolds. Both bacterial species formed dense populations and secreted 
extracellular polysaccharides (EPS) on the RIF-free scaffolds.  PA or SE exhibited 
minimal colonization on both RIF scaffolds.  
 
6.2 Motivation and Aims 
Major orthopaedic surgeries such as total joint arthroplasty (ie. hip and knee), 
internal fracture fixation, and spinal fusion require invasive surgeries that are 
accompanied with the potential for life-threatening infections [266].  Amongst the most 
popular clinical strategies for combating infection is two-stage re-implantation in which 
infected tissue is removed along with the implant [130], and antibiotic-loaded cement is 
often loaded into the vacated space to prevent wound closure [267].  After approximately 
six weeks of local and systemically administered antibiotics, the patient receives another 
implant.  Thus, a patient would undergo three surgeries and withstand an infection plus 
powerful antibiotics such as vancomycin or methicillin [122].  Prophylactic measures 
such as antibiotic implant coatings [268] offer a means to reduce the occurrence and 
severity of these infections. 
Electrospun nanofibers have been effective in delivering biologically-active 
molecules such as growth factors [269, 270], short peptides [215], and antibiotics [271].  
The deposited fibers may form a surface coating on an implant or a stand-alone 
nanofibrous matrix from which a desired molecule can elute [158].  By releasing these 
molecules locally, highly-effective concentrations may be achieved while avoiding 
potentially toxic effects by reducing the overall systemic concentrations.  Furthermore, 
drugs such as gentamicin or vancomycin are ineffective when taken orally, and localized 




Staphylococcus Epidermis (SE) and Pseudomonas Aeruginosa (PA) are Gram-
positive and Gram-negative microbes, respectively.  SE is involved with approximately 
30% of bacterial colonies in clinical orthopaedic implants [272, 273].  PA is the most 
common non-staphylococcus bacterial strain found in clinical orthopaedic infections 
[273].  Although infection rates are low for closed fractures, up to 60% of all open 
fractures are infected when the injury occurs [274].  It should be noted that even for the 
more favorable closed-fracture scenario, prophylactic antibiotic administration has been 
shown to significantly reduce incidence of infections [275].  Thus, for implantation 
surgeries, including an antibiotic treatment, even if the risk of infection is low, is likely to 
help reduce hospital-acquired infections which cost an average of $68,000 per patient 
[276]. 
In this chapter, PCL nanofibers were loaded with rifampicin (RIF), an antibiotic that is 
most effective against Gram-positive bacteria.  Scaffolds were loaded with two 
concentrations of RIF, and the release profile of RIF from PCL nanofibers was 
measured.  Then the bactericidal efficacy of PCL-RIF nanofiber scaffolds was evaluated 
using a Gram-positive and Gram-negative strain of bacteria – Staph E. and Pseud. A. 
respectively – in static conditions.   
 
6.3 MATERIALS AND METHODS 
6.3.1 Fabrication & Characterization of Nanofiber Scaffolds 
Nanofiber scaffolds were fabricated by electrospinning 80,000 molecular weight 
PCL polymer (Sigma) solution (12% w/w) with 3% oleic acid sodium salt (Sigma), and 
0%, 9% or 16% Rifampicin (RIF).  PCL, OLA, and RIF were dissolved in a solvent 
mixture of 3:1 (volume ratio) chloroform:methanol  (Sigma) and loaded into a glass 




by a syringe pump (Harvard Apparatus) at a rate of 1.8-2.1 mL/hr.  A high-voltage power 
supply (Gamma High Voltage Research, model ES30P-10W/DAM) was used to apply 
voltage in the range of 18-21 kV to the blunt-tip catheter that was positioned 4-4.5‖ from 
the grounded collector plate.  
In order to examine the morphology of the nanofiber scaffolds and determine the 
fiber diameter, they were sputter-coated with 10 nm of gold and imaged under high 
magnification using a field-emission scanning electron microscope (SEM, JEOL JSM-
6500F). Fiber diameters were measured using SEM image analysis software.  Ten 
measurements were made on each scaffold with nmin=30 and size distribution histogram 
was plotted. 
Thermal characterization of the nanofiber scaffolds was performed to determine 
the effect of electrospinning process on polymer crystallinity and thermal stability.  
Differential scanning calorimetry (DSC, TA Instruments DSC 2920) was used to 
determine the polymer crystallinity in different nanofiber scaffolds. The scaffolds were 
heated from 5oC to 120oC at 5oC/min and the crystallinity of a sampled was calculated by 
the following equation: 
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where Hm,sample is the enthalpy of melting of the nanofiber scaffold and Hm,std is the 
enthalpy of melting of 100% crystalline PCL (Hm,std = 139 J/g) [174].   
 
6.3.2 Rifampicin release from nanofibers 
 The release profile of rifampicin (RIF) from PCL nanofibers was evaluated at hours 1, 
4, 8, and 24.  10 mm discs were cut out using a biopsy punch and then placed in 1mL 




aliquot of PBS was removed and replaced with 200 L of fresh PBS. Each aliquot was 
immediately stored in a -80oC freezer until the completion of the release study.  The 
concentration of antibiotic in each aliquot was measured colorimetrically by subtracting 
the absorbance at 690 nm from 570 nm.  Concentration data points were fitted to the 









In this equation, t is a time point, Mt, and Mtot are the mass released at time, t, and the 
total mass within the scaffold.  This means that Mt/Mtot is the percent of antibiotic 
released at t.  The constant k accounts for the ground matrix (polymer nanofibers) and 
drug (RIF) characteristics, and n is the diffusional exponent [277, 278]. 
 
6.3.3 Static bacterial challenge 
 Scaffolds were placed in 3 mL of lysogeny or trypticase soy broth and inoculated with 
either Pseudomonas aeruginosa (PA) or Staphylococcus epidermidis (SE), respectively.  
Each hour for 0-6 hours, aliquots of the medium were removed and filtered through a 
100nm membrane.  Trapped bacteria were then stained with Live/Dead BacLight™ 
(Invitrogen) stains and counted microscopically.  BacLight™ contains SYTO 9 and 
propidium iodide which stain live and dead bacteria respectively.  SYTO 9 is a 
proprietary stain that gives a fluorescent signal for live bacterial cells.  Propidium iodide 
(PI) is impermeable to intact cell membranes, and live cells will exlude this dye.  When 
bacteria no longer maintain their cell membranes, the PI can diffuse into cells and 
intercalate DNA.  SYTO 9 (ex: 480 nm; em: 550 nm) and PI (ex: 490; em: 635 nm) were 
visualized at identical locations and the images were used to count live and dead 




and dehydrated in an ethanol wash series. Scaffolds were sputter coated with 7 nm of 
gold and examined under SEM. 
 The growth of the population was modeled, with a focus on the exponential 
population growth phase (Figure 6.1).  The exponential growth constant, , for the 






When this equation is integrated over time, t, and the terms arranged to solve for  it 











where N is the number of bacteria, also referred to as the population. 
 
6.3.4 Statistical analysis 
The scaffold characterization methods 
evaluating the effects of RIF on fiber 
diameter and crystallinity were evaluated 
with t-tests.  For the release study, a 
nonlinear regression was used to fit the 
constants for equation 1 using a least-
squares method.  For bacterial growth 
data, the population values were analyzed using linear regression on a log(10) scale to 
determine the significance of the effects of hours, RIF, and hours*RIF.  Significance was 
defined at the 95% confidence level.  All analysis was performed in Excel as well as in 
JMP statistics software (SAS).   
 
Figure 6.1 – Stages of bacterial population 






6.4.1 Fabrication and Characterization of Nanofiber Scaffolds 
 All scaffolds were fabricated to contain 3% OLA as a process stabilizer, and RIF-
loaded scaffolds were fabricated to have two RIF concentrations – 9% or 16% of the 
solid scaffold weight.  In order to characterize the architecture of the scaffolds, scaffolds 
were examined under SEM and their fiber diameters were measured.  The 9% RIF 
scaffolds were significantly different from the other two scaffolds, and their 
measurements showed the narrowest distribution and the smallest mean fiber diameter 
(Figure 6.2).  The 16% RIF scaffolds had the flattest distribution of fiber diameters, with 
quite a few very large fibers, and SEM images reflect this relatively even distribution.  
Although the mean fiber diameters for RIF-free and 16% RIF scaffolds were statistically 
similar, their distributions are clearly different.  Similarly, the fiber diameters for RIF-free 
and 10% RIF scaffolds were statistically different, but their fiber diameter distributions 
were fairly similar except for the occurrence of larger fibers on RIF-free scaffolds.  
 Differential scanning calorimetry (DSC) results showed that the PCL in RIF-free 
scaffolds had the highest value of crystallinity (Figure 6.3), and a t-test revealed that this 
difference was significant compared to both RIF scaffolds. The test between 9% and 
16% RIF scaffolds was not significantly different. 
 
6.4.2  Rifampicin release from nanofibers 
 The release of RIF from nanofiber scaffolds was studied by removing small aliquots of 
media (PBS) at hours 1, 4, 8, and 24.  The concentration of the RIF within each aliquot 
was calculated by generating standard curves and measuring the absorbance at 475 




mass released of RIF, and the percent released was fit 
to equation 2.  The results for percent release (Figure 6.4 (A)) showed that both 
scaffolds initially released a burst of antibiotic and then the release quickly died off.  9% 
RIF scaffolds released a greater percent of their theoretical loading, and the release 
occurred more rapidly than 16% scaffolds.  The models for both release profiles fit 
experimentally-measured values very closely for the initial release, which took place 
during the first 8 hours.  Between eight and twenty-four hours, only a small percent of 
mass was released and the models predicted a much larger zero-order release which 
did not match the measured trend.  The mass release (Figure 6.4 (B)) showed that 9% 
scaffolds released most of the mass very quickly, within the first 4 hours, while 16% 
scaffolds released most of the mass by 8 hours.  The difference in mass released was 
 
Figure 6.2 – SEM of scaffolds, mean fiber diameters, and fiber diameter histograms.  
Magnification for RFP-free scaffolds is 2500x, magnification for 9% and 16% RFP scaffolds is 
2000x.  Scale bar for all SEM images is 10 m.  Star for fiber diameter plot indicates 





Figure 6.3 – % crystallinity measured by 
differential scanning calorimetry 
 
Figure 6.4 - % RIF release for 24 hours with the model parameters, K and n, 
for the percent of RIF released from 9% and 16% scaffolds 
clear after just 1 hour and the total mass 
released by 16% scaffolds was approximately 
twice the amount released by 9% scaffolds. 
 
6.4.3 Static bacterial challenge 
 Two strains of bacteria, Gram-negative 
Psuedomonas Aeruginosa (PA) and Gram-
positive Staphylococcus Epidermis (SE), 
were used to determine the inhibitory effect of 
RIF release on bacterial colony growth.  Bacterial colonies were sampled, filtered, and 
fluorescently stained with a commercially-available kit for microscopic population 
counting.  Because of rapid population growth, a series of different dilutions (Figure 6.5) 
were used to ensure that cell counts were accurate.  The live cell images (Figure 6.6) 
show that even 
with the 
significantly 










Figure 6.5 – Dilutions used for 
bacterial analysis  
 
Figure 6.6 – Live bacteria stained by SYTO 9™ at hours 0-6 on RIF-free, 9% RIF, or 16% RIF 
scaffolds 
  The quantification of both bacterial colonies 
showed strong growth on RIF-free scaffolds, with 
exponential growth constants () greater than 1 
(Figures 6.7 and 6.8).  For PA, the live 
populations on both RIF scaffolds were nearly 
constant, with small increases by hour 3 and then 
decreases back to initial population levels by hour 6.  SE live cell populations also had 
only small changes during the 6 hour study.  However, 9% and 16% RIF scaffolds 
caused decreases in their bacterial populations of 70% and 50% respectively.   
 After 6 hours, scaffolds were removed from the broth and the bacteria were fixed for 
examination under SEM.  The differences observed in population growth were reflected 
in the SEM images for both PA and SE.  On RIF-free scaffolds, both bacterial strains 
multiplied prolifically and had populated scaffold surfaces in dense colonies (Figures 6.9 
(A & B) and 6.10 (A & B)).  Differences between the behaviors of the two bacterial 
strains were also apparent on RIF-free scaffolds, as SE laid down extracellular 
polysaccharide (EPS) in sparingly (Figure 6.9 (B)), while PA produced abundant EPS 





Figure 6.7 – Population growth by 
pseudomonas aeruginosa 
on the surface.  In fact, the EPS produced by 
PA was so thick that it obstructed the view into 
the interior of the scaffolds over large portions 
of the surface (Figure 6.10 (A)).  Both strains 
also showed up very sparingly on RIF 
scaffolds.  There were no visible differences in 
bacterial populations between 9% and 16% 
RIF scaffolds for either bacterial strain.  Only 
an occasional pair of SE were observed on 
either RIF scaffold (Figures 6.9 (C & D)) and 
only one or two bacteria had produced EPS.  
PA also only appeared as an occasional pair 
on the RIF scaffold surfaces with minimal EPS 
(Figures 6.10 (C & D)).  It should be emphasized that for both bacterial strains, the 
amount of EPS observed was very low.   
 
6.5 DISCUSSION 
 Nanofiber scaffolds were fabricated to have either 9% or 16% w/w of rifampicin (RIF), 
an antibiotic with bactericidal action primarily against Gram-positive bacteria [128, 279].  
The scaffolds showed morphological differences, and 9% RIF scaffolds had a mean fiber 
diameter ~150-200 nm smaller than both other scaffolds (Figure 6.2).  The 9% RIF 
scaffolds were significantly different from the other two scaffolds, and the differences in 
fiber diameter distribution were also apparent from the histogram.  Further, PCL 
crystallinity was reduced by adding RIF at both concentrations in a statistically-significant 





Figure 6.8 – Population growth by 
staphylococcus epidermis 
 Both of these results are important to keep 
in mind for PCL-based scaffolds for bone 
tissue engineering.  Architectural 
considerations affect different cell 
phenotypes in different manners, and cells 
with osteoblast and fibroblast phenotypes 
have demonstrated relative insensitivity to 
changes in fiber diameters between ~200-
800 nm [140] and fiber alignments [280].  
Thus, the significant difference in fiber 
diameter between 9% RIF scaffolds and both 
other scaffolds is less likely to influence new 
cell colonization than the release of high local 
concentrations of RIF. The decrease in crystallinity due to RIF (Figure 6.3) may increase 
the degradation rate because hydrolysis of ester bonds in PCL occurs preferentially in 
amorphous regions [109, 244].  PCL degradation occurs relatively slowly in the absence 
of hydrolyzing enzymes [237, 243], and approximating scaffold mass loss with new 
tissue deposition has been identified as an ideal characteristic of biodegradable 
scaffolds [281].   
 The release of RIF from 9% and 16% scaffolds were fit to a diffusion-mediated 
release model (equation 2) [277].  Multiple iterations of analyses were performed varying 
B between 0% and 50% of the t=1 hour release values for either 9% or 16% RIF 
scaffolds. However, none of the iterations led to a fit of n close to 0.45, which is the 
theoretical value for cylindrical geometries of non-swellable matrices [277].  The 




0.45 for cylindrical substrates such as nanofibers.  The values calculated by JMP were 
0.188 and 0.104 for 16% and 9% RIF scaffolds, respectively.  In an attempt to more 
closely match the theoretical value of 0.45, an offset factor was added into the equation, 





t  (Equation 6.4) 
This approach did not bring the value of n closer to 0.45.  In fact, the lowest standard 
error values for the model were achieved by eliminating this offset factor.   
 The release profiles for both RIF scaffolds showed a short burst of drug release 
(Figure 6.4), followed by a period of only nominal drug release.  This is a common 
observation in studies of small-molecule release from nano-scale substrates [282].   The 
model parameters were accurate in fitting a predicted release profile to the initial burst 
release profile which lasted approximately 8 hours.  After that point though, the models 
for both scaffolds predicted a continued release whereas the measured RIF 
concentrations indicated that release had ceased.  The model for 9% RIF scaffolds 
would approach an asymptotic value of ~80% release by day 7 while the model for 16% 
RIF scaffolds would approach 100% release by day 7, which illustrates the differences in 
models due to changes in the diffusional exponential, n.  Neither scaffold released 100% 
of the theoretical RFP mass, which suggests that the encapsulation efficiency for RIF 
was less than 100%.  It should be noted that the % release may also not be 100% of the 
loaded RIF mass.  Therefore, it will be important to measure the encapsulation efficiency 




 In order to test the effectiveness of RIF released from nanofibers scaffolds, scaffolds 
were inoculated with either staphylococcus epidermis (SE) or pseudomonas aeruginosa 
(PA) and the population growth was compared against RIF-free control scaffolds.  RIF is 
viewed with some skepticism clinically because bacteria can develop resistance with a 
relatively simple mutation in the  subunit of RNA polymerase [129].  Additionally, oral 
dosage regiments should be increased in frequency because the serum half-life 
decreases due to increased metabolism rates as liver enzymes are up-regulated in 
response to the RIF administration.  However, RIF is appealing because it can act 
against bacteria in any state of activity [127].   
 
Figure 6.9 – SEM images of staphylococcus epidermis on RIF-free (A & B), 9% RIF (C), and 
16% RIF (D) scaffolds 6 hours after inoculation.  Magnification for A, C, and D is 2500x and 




 The results showed a clear inhibition of bacterial population growth through 6 hours 
in static conditions (Figures 6.7 and 6.8).  Additionally, SEM images of scaffolds after 6 
hours showed that neither PA nor SE were able to form biofilms on either RIF scaffold, 
while both strains were able to form biofilms on RIF-free scaffolds (Figures 6.9 and 
6.10).  In particular, PA formed thick biofilms on large portions of the scaffold surfaces 
(Figure 6.10 (A)).  Interestingly, there did not appear to be any additional benefit with 
16% RIF scaffolds over the 9% scaffolds.  The static nature of the experimental 
conditions may explain this observation.   
 The static conditions permit a cumulative release of RIF without any clearance 
except for small aliquots removed each hour, but those aliquots represented only a few 
 
Figure 6.10 – SEM images of pseudomonas aeruginosa on RIF-free (A & B), 9% RIF (C), and 
16% RIF (D) scaffolds 6 hours after inoculation.  Magnification for A, C, and D is 2500x and 




percent of the total volume.  This is a key detail for interpreting the translation of these 
scaffolds into clinical settings.  The static nature of this ex vivo model is appropriate for 
healing scenarios in which extracellular fluid is cleared slowly. For example, spaces 
adjacent to cauterized tissues where blood flow is temporarily obstructed would have a 
slow RIF clearance, and this slow clearance would lead to sustained high RIF 
concentrations until blood flow was restored.  However, highly-dynamic environments 
such would clear the RIF quickly into the blood stream where it would be metabolized by 
the liver and gall bladder [283].  Thus, further evaluation in dynamic systems should be 
pursued to determine the efficacy of scaffolds with 9% or 16% RIF. 
 
6.6 Conclusions 
 Poly(-caprolactone) nanofiber scaffolds were fabricated to include either 9% or 16% 
w/w rifampicin (RIF), and the RIF release and bactericidal efficacies from the scaffolds 
were evaluated against RIF-free control scaffolds.  There were significant differences 
between the RIF release profiles, though both scaffolds showed an initial burst release 
and RIF release did not increase after 8 hours.  The concentrations released by both RIF 
scaffolds into static conditions were sufficient to prevent bacterial colony growth through 
6 hours for PA and SE.  Both bacterial strains were able to grow prolifically on RIF-free 
scaffolds and produce biofilms quickly.  These results demonstrate the efficacy of 
locally-delivered small molecule antibiotics in static conditions, and the same scaffolds 
will be evaluated in dynamic conditions in the future. 
 
6.7 Future work 
 There are two areas of RIF release needing attention.  First, the measured mass 




the encapsulation efficiency is also less than 100%.  Thus two separate experiments are 
currently being prepared in order to measure the encapsulation efficiency.  First, 
thermogravimetric analysis (TGA) can measure the mass of PCL lost, demonstrating the 
mass or RIF remaining.  Colorimetric measurements of re-dissolved scaffolds will 
provide a second measure of RIF concentration.  Similar experiments will be performed 
for scaffolds after the 7 day release study in order to measure the release efficiency.   
 Additional experiments examining the efficacy of these RIF scaffolds in dynamic 
conditions will also be performed.  These experiments will be designed to mimic an 
environment that scaffolds would be exposed to if they were used as a vascular 
constructs.  In that case, a short burst of antibiotics for eight hours may not be sufficient 
to eliminate robust infections.  To address these difficulties, additional antibiotics and 
release mechanism will be designed into the scaffolds so that release of additional 
antibiotics can take place following the initial burst of RIF.  Finally, the effects of RIF 
release on primary mammalian cells will also be evaluated.  Given the short release 
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 This work aimed to develop poly(-caprolactone) nanofiber scaffolds with osteogenic 
design factors incorporated into the fibers, and also for localized antibiotic delivery.  The 
two design factors, oleic acid (OLA) and hydroxyapatite (HAp), represented soluble and 
insoluble signals, respectively, which elicited differential responses from marrow stromal 
cells (MSCs).  In vitro, OLA appeared to inhibit cell spreading and metabolic activity in 
maintenance conditions while it increased osteogenic phenotypic behaviors.  
Additionally, OLA differentially affected the expression of two peroxisome proliferator-
activator receptors (PPARs) which have been associated with osteoblastogenesis.  HAp 
also differentially affected osteoblast behaviors, but in a less-clear manner.  Although 
alkaline phosphatase was slightly increased, two other key genes, osteopontin and type 
I collagen, were down-regulated in vitro.  However, in vivo HAp incorporation into PCL 
nanofiber scaffolds proved to be a strong enhancer of bone formation in calvarial 
defects, while OLA showed some positive synergy with HAp as an osteogenic factor.  
Finally, the release of a small-molecule antibiotic, rifampicin (RIF) was effective against 
both Gram-positive and Gram-negative bacterial strains separately and in static culture 
conditions.  The release profiles for RIF-eluting scaffolds showed a fast burst release of 
RIF with a cessation by 24 hours.  This burst effect provides a strong motivation for 
materials engineering by incorporating additional antibiotics with slower release 
mechanisms. 
 Future work will be focused on profiling the release of OLA from nanofibers scaffolds, 
understanding the manner with which cells interpret mineralization in their extracellular 
environment, and further developing and evaluating antibiotic delivery from these 
nanofiber scaffolds.   
 
